Selexipag / ACT- 293987  
Pulmonary Arterial Hypertension  
Protocol AC -065A308 
 
TRITON  
The efficacy and safety of initial triple versus initial dual oral combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi- center, 
double -blind, placebo -controlled, Phase 3b study  
  
Study Phase:  3b 
EudraCT Number: 2015-003438-28 
Status and version: Final Version 6  
Date:  4 December  2018 
Actelion document number 
(Doc No.):  D-18.392 
 
Confidentiality statement  
The information contained in this document, especially unpublished data , is the property of the sponsor of 
this study, Actelion Pharmaceuticals Ltd. It is therefore provided to you in confidence as an investi gator, 
potential investigator, or consultant, for review by you, your staff, and an Ethics Committee or Institutional Review Board. It is understood that this information will not be disclosed to others without written authorization from Actelion Pharmaceuticals Ltd, except to the extent necessary to obtain informed consent from those persons to whom the study treatment may be administered.
  
[STUDY_ID_REMOVED]
SPONSOR CONTACT DETAILS 
SPONSOR  
 ACTELION Pharmaceuticals Ltd  
Gewerbestrasse 16  
CH-4123 Allschwil 
Switzerland  
 +41 61 565 65 65  
Clinical Trial Physician  Maziar Assadi  Gehr, MD  
  
Fax  
e-mail  
MEDICAL HOTLINE  
Toll phone number:  
+41 61 227 05 63  Country -specific toll and toll -free phone numbers 
for the Medical Hotline can be found in the 
Investigator Site File  
 
  
ACTELION CONTRIBUTORS TO THE PROTOCOL 
Clinical Trial Scientist  , Associate Directo r 
 
Clinical Trial Statistician  Nicolas Martin, Expert Statistician  
 
Clinical Trial Physician  Maziar Assadi  Gehr, Global Medical Affairs 
Physician  
 
Drug Safety Physician  , Associate Director  
 
  
COORDINATING INVESTIGATOR 
Name / Title  Address  
Marius Hoeper, MD  University of Hannover, Medical School  
 
, G
ermany  
 
 
PPD
PPD
PPD
PPD
PPD
PPD
[STUDY_ID_REMOVED]
CONTRACT RESEARCH ORGANIZATIONS INFORMATION 
 
CENTRAL LABORATORY  
 ACM Global Central Laboratory  
23 Hospital Fields Road York YO10 4DZ, UK 
 
CENTRAL 
RANDOMIZATION  
 Almac Clinical Technologies LLC  
25 Fretz Road Souderton, PA 18964, USA 
 
CRO  
 Chiltern International  
171 Bath Road Slough, Berkshire SL1 4AA, UK 
 
Biostati stics Datamap  GmbH  
Munzinger Strasse 5a  
79111 Freiburg, Germany 
 
Home Phlebotomy  Global Care Clinical Trials Ltd  
2201 Waukegan Road Suite 270 Bannockburn, IL 60015, USA 
 
A list of site -specific contact details for Contract Research Organizations ( CROs ) can 
be found in the Investigator Site File. 
 
  
[STUDY_ID_REMOVED]
SIGNATURE PAGE FOR ACTELION PHARMACEUTIC ALS LTD  
Hereinafter called Actelion  
 Treatment name / number Selexipag  / ACT -293987 
Indication Pulmonary arterial h ypertension 
Protocol number, study acronym, study title AC-065A308, TRITON : The efficacy and safety of initial triple versus initial dual oral 
combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study.  I approve the design of this study. 
 
 
 
  
PPD
PP
D
PPD
PPD
[STUDY_ID_REMOVED]
INVESTIGATOR SIGNATURE PAGE 
 Treatment name / number Selexipag  / ACT -293987 
Indication Pulmonary arterial h ypertension 
Protocol number, study acronym, study title AC-065A308, TRITON : The efficacy and safety of initial triple versus initial dual oral 
combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi-center, double-blind, placebo-controlled, Phase 3b study . 
I agree to the terms and conditions relating to this study as defined in this protocol  including 
appendices , the electronic Case Report Form (CRF), and any other protocol -related 
documents. I fully understand that any changes instituted by the investigator(s) without previous agreement with the sponsor would constitute a protocol deviation, including any ancillary studies or procedures performed on study subjects (other than those procedures necessary for the wellbeing of the subjects).  
I agree to conduct this study in accordance with the latest version s of the Declaration of 
Helsinki principles, International Council for  Harmonisation (ICH) Good Clinical Practice 
(GCP) guidelines, and applicable regulations and laws. I will obtain approval by an Institu tional Review Board or Independent Ethics Committee (IRB/IEC) prior to study start 
and signed informed consent from all subjects included in this study. If an amendment  to 
the protocol is necessary, I will obtain approval by an IRB/IEC and ensure approval by regulatory authorities (if applicable) have been obtained before the implementation of changes described in the amendment. I will allow direct access to source docum ents and 
study facilities to sponsor representative(s), particularly monitor(s) and auditor(s), and agree to inspection by regulatory authorities or IRB/IEC representative. I will ensure that the study treatment(s) supplied by the sponsor are being used only as described in this protocol. I confirm herewith that the sponsor is allowed to enter and utilize my professional contact details and function in an electronic database for internal purposes and for submission to regulatory  authorities worldwide. 
 Country  Site 
number  Town  Date   Signature  
Principal 
Investigator        
[STUDY_ID_REMOVED]
TABLE OF CONTENTS 
SPONSOR CONTACT DETA ILS ......................................................................................2  
ACTELION CONTRIBUTORS TO THE PROTOCOL  .....................................................2  
COORDINATING INVESTIGATOR .................................................................................2  
CONTRACT RESEARCH OR GANIZATIONS INFORMAT ION ...................................3  
LIST OF ABBREVIATION S AND ACRONYMS  ..........................................................13  
PROTOCOL SYNOPSIS AC -065A308 ............................................................................16  
1 BACKGROUND  .........................................................................................................29  
1.1 Indication ......................................................................................................29  
1.2 Study treatments  ...........................................................................................29  
1.2.1  Macitentan  ........................................................................................29  
1.2.1.1  Nonclinical results  ...................................................................30  
1.2.1.2  Clinical pharmacology  ............................................................30  
1.2.1.3  Clinical efficacy  ......................................................................30  
1.2.1.4  Summary of safety profile  .......................................................31  
1.2.2  Tadalafil  ............................................................................................31  
1.2.2.1  Nonclinical results  ...................................................................31  
1.2.2.2  Clinical pharmacology  ............................................................31  
1.2.2.3  Clinical efficacy  ......................................................................31  
1.2.2.4  Summary of safety profile  .......................................................32  
1.2.3  Selexipag  ...........................................................................................32  
1.2.3.1  Nonclinical results  ...................................................................33  
1.2.3.2  Clinical pharmacology  ............................................................33  
1.2.3.3  Clinical efficacy  ......................................................................33  
1.2.3.4  Summary of safety profile  .......................................................33  
1.3 Purpose and rationale of the study ................................................................34  
2 STUDY OBJECTIVES  ...............................................................................................35  
2.1 Primary objective  ..........................................................................................35  
2.2 Secondary objectives ....................................................................................35  
2.3 Exploratory objectives ..................................................................................35  
3 OVERALL STUDY DESIGN AND PLAN  ...............................................................36  
3.1 Study design .................................................................................................36  
[STUDY_ID_REMOVED]
3.2 Study design rationale ..................................................................................38  
3.3 Study committees  .........................................................................................39  
4 SUBJECT POPULATION ..........................................................................................40  
4.1 Subject population description .....................................................................40  
4.2 Rationale for the selection of the study population ......................................40  
4.3 Inclusion criteria  ...........................................................................................40  
4.4 Exclusion criteria  ..........................................................................................41  
4.5 Criteria for women of childbearing potential ...............................................43  
4.5.1  Definition of childbearing potential ..................................................43  
4.5.2  Acceptable methods of contraception ...............................................43  
4.6 Medical history  .............................................................................................44  
5 TREATMENTS  ..........................................................................................................45  
5.1 Study treatment  .............................................................................................45  
5.1.1  Investigational treatment : description and rationale .........................45  
5.1.2  Comparator treatment: description and rationale ..............................45  
5.1.3  Study treatment adm inistration  .........................................................45  
5.1.4  Treatment assignment  .......................................................................47  
5.1.5  Blinding ............................................................................................48  
5.1.6  Unblinding ........................................................................................48  
5.1.6.1  Unblinding for final analyses ..................................................48  
5.1.6.2  Unblinding for interim analyses ..............................................48  
5.1.6.3  Unblinding for suspected unexpected serious adverse reactions
 .......................................................................................48  
5.1.6.4  Emergency procedure for unblinding ......................................49  
5.1.7  Study treatment supply .....................................................................49  
5.1.7.1  Study treatment packaging and labeling  .................................49  
5.1.7.2  Study treatment distribution and storage .................................50  
5.1.7.3  Study treatment dispensing .....................................................50  
5.1.7.4  Study treatment return and destruction ...................................50  
5.1.8  Study treatment accountability and compliance with study treatment  ...........................................................................................50
 
5.1.8.1  Study treatment accountability  ................................................50  
5.1.8.2  Study treatment compliance  ....................................................51  
5.1.9  Study treatment dose adjustments and interruptions ........................51  
5.1.10  Premature discontinuation of study treatment  ..................................52  
5.1.11  Study- specific criteria for interruption / premature 
discontinuation of study treatment ....................................................52  
5.2 Previous and concomitant therapy ................................................................56  
[STUDY_ID_REMOVED]
5.2.1  Definitions  ........................................................................................56  
5.2.2  Reporting of previous/concomitant therapy in the eCRF .................57  
5.2.3  Allowed concomitant therapy ...........................................................57  
5.2.4  Forbidden concomitant therapy ........................................................57  
5.2.5  Rescue therapy  ..................................................................................58  
6 STUDY ENDPOINTS  ................................................................................................58  
6.1 Efficacy endpoints ........................................................................................58  
6.1.1  Primary efficacy endpoint  .................................................................58  
6.1.2  Secondary efficacy endpoints ...........................................................59  
6.1.3  Exploratory efficacy endpoints .........................................................59  
6.2 Safety endpoints  ...........................................................................................60  
6.3 Biomarker endpoints .....................................................................................60  
7 STUDY ASSESSMENTS  ...........................................................................................60  
7.1 Screening/baseline assessments  ....................................................................61  
7.1.1  Eligibility criteria  ..............................................................................61  
7.1.2  Demographic and baseline characteristics  ........................................61  
7.1.3  Medical history  .................................................................................61  
7.1.4  Previous therapies .............................................................................61  
7.2 Efficacy assessments  ....................................................................................61  
7.2.1  RHC  ..................................................................................................61  
7.2.2  6-minute walk test, Borg dyspnea index ...........................................62  
7.2.3  WHO functional class  .......................................................................62  
7.2.4  Circulating biomarkers of right ventricular function and structure  ............................................................................................62
 
7.2.5  Other efficacy assessments  ...............................................................62  
7.3 Safety assessments  ........................................................................................62  
7.3.1  (Serious) adverse events  ...................................................................63  
7.3.2  Contraception methods and pregnancy testing  .................................63  
7.3.3  Vital signs  .........................................................................................63  
7.3.4  Body weight ......................................................................................63  
7.3.5  Physical examination  ........................................................................63  
7.3.6  Concomitant therapies ......................................................................63  
7.3.7  Laboratory assessments  ....................................................................63  
7.3.7.1  Type of laboratory ...................................................................63  
7.3.7.2  Laboratory tests  .......................................................................64  
8 SCHEDULE OF VISITS  ............................................................................................66  
8.1 Screening period  ...........................................................................................66  
[STUDY_ID_REMOVED]
8.2 Treatment period  ...........................................................................................67  
8.2.1  Day 1 (randomization) visit ..............................................................67  
8.2.2  Day 8 visit .........................................................................................68  
8.2.3  Day 15 visit .......................................................................................68  
8.2.4  Weekly phone calls during up- titration  ............................................68  
8.2.5  Week 12 visit ....................................................................................68  
8.2.6  Week 26 visit ....................................................................................69  
8.2.7  Month 12, 18, 24, 30, etc. visits ........................................................69  
8.2.8  EOMOP visit  .....................................................................................69  
8.2.9  EOT visit  ...........................................................................................70  
8.2.10  Unscheduled visits ............................................................................70  
8.3 Safety follow -up ...........................................................................................70  
8.3.1  EOS visit  ...........................................................................................70  
9 STUDY COMPLETION AND POST -STUDY TREATMENT/MEDICAL 
CARE  ..........................................................................................................................71  
9.1 Study completion  ..........................................................................................71  
9.2 Premature withdrawal of subjects from study  ..............................................71  
9.3 Premature termination or suspension of the study ........................................72  
9.4 Medical care of subjects after study completion/withdrawal from study ..............................................................................................................72
 
10 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS  ...........................73  
10.1  Adverse events  ..............................................................................................73  
10.1.1  Definitions of adverse events ............................................................73  
10.1.2  Intensity of adverse events  ................................................................73  
10.1.3  Relationship to study treatment ........................................................74  
10.1.4  Adverse events associated to study design or protocol-mandated procedures ..........................................................74
 
10.1.5  Reporting of adverse events ..............................................................74  
10.1.6  Follow-up of adverse events .............................................................75  
10.2  Serious adverse events  ..................................................................................75  
10.2.1  Definitions of serious adverse events ...............................................75  
10.2.1.1  Serious adverse events  .............................................................75  
10.2.2  Reporting of serious adverse events .................................................75  
10.2.3  Follow-up of serious adverse events .................................................76  
10.2.4  After the [30 -day] follow-up period .................................................76  
10.2.5  Reporting procedures ........................................................................76  
10.3  Pregnancy  .....................................................................................................77  
10.3.1  Reporting of pregnancy ....................................................................77  
[STUDY_ID_REMOVED]
10.3.2  Follow-up of pregnancy ....................................................................77  
10.4  Study safety monitoring  ................................................................................77  
11 STATISTICAL METHODS  .......................................................................................77  
11.1  Analysis sets  .................................................................................................78  
11.1.1  Screened Analysis Set  .......................................................................78  
11.1.2  Full Analysis Set ...............................................................................78  
11.1.3  Modified Full Analysis Set ...............................................................78  
11.1.4  Per-protocol Set ................................................................................78  
11.1.5  Safety Set  ..........................................................................................78  
11.1.6  Usage of the analysis sets  .................................................................78  
11.2  Variables  .......................................................................................................79  
11.2.1  Primary efficacy variable  ..................................................................79  
11.2.2  Secondary efficacy variables  ............................................................79  
11.2.3  Other efficacy variables  ....................................................................79  
11.2.4  Safety variables  .................................................................................79  
11.3  Description of statistical analyses  .................................................................79  
11.3.1  Overall testing strategy  .....................................................................79  
11.3.2  Analysis of the primary efficacy variable  .........................................80  
11.3.2.1  Hypotheses and statistical model ............................................80  
11.3.2.2  Handling of missing data  .........................................................80  
11.3.2.3  Main analysis  ...........................................................................80  
11.3.2.4  Supportive/sensitivity analyses ...............................................81  
11.3.2.5  Subgroup analyses ...................................................................81  
11.3.3  Analysis of the secondary efficacy variables  ....................................81  
11.3.4  Analysis of the other efficacy variables  ............................................82  
11.3.5  Analysis of the safety variables  ........................................................82  
11.3.5.1  Adverse ev ents ........................................................................83  
11.3.5.2  Laboratory variables  ................................................................83  
11.3.5.3  Vital signs and body weight  ....................................................84  
11.3.6  Analysis of other variable(s) .............................................................84  
11.4  Interim analyses  ............................................................................................84  
11.5  Sample size  ...................................................................................................85  
11.5.1  Sample size justification  ...................................................................85  
11.5.2  Sample size sensitivity  ......................................................................87  
12 DATA HANDLING  ....................................................................................................88  
12.1  Data collection  ..............................................................................................88  
12.2  Maintenance of data confidentiality  .............................................................88  
12.3  Database management and quality control  ...................................................88  
[STUDY_ID_REMOVED]
13 PROCEDURES AND GOOD CLINICAL PR ACTICE  .............................................89  
13.1  Ethics and Good Clinical Practice  ................................................................89  
13.2  Independent Ethics Committee / Institutional Review Board  ......................89  
13.3  Informed consent ..........................................................................................90  
13.4  Compensation to subjects and investigators .................................................91  
13.5  Protocol adherence/compliance  ....................................................................91  
13.6  Protocol amendments ...................................................................................91  
13.7  Essential documents and retention of documents .........................................91  
13.8  Monitoring ....................................................................................................92  
13.9  Investigator Site File  .....................................................................................93  
13.10  Audit .............................................................................................................94  
13.11  Inspections ....................................................................................................94  
13.12  Reporting of study results and publication ...................................................94  
14 REFERENCES  ............................................................................................................95  
  
LIST OF TABLES 
 Table 1
 Visit and assessment schedule  ......................................................................27  
Table 2  Double-blind up-titration scheme up to the Week 12 visit ...........................47  
Table 3  Mean and SD for PVR, log-transformed PVR and change from baseline on log-scale  ........................................................................................................86
 
Table 4  Sample sizes needed for 90% power at final analysis, and stopping value for futility at interim analysis (two -sided α  = 0.05, SD = 0.5, information 
time = 0.33) ...................................................................................................87
 
  
LIST OF FIGURES 
 Figure 1
 Study periods (subject level) .........................................................................37  
Figure 2  Planned duration (study level) ......................................................................38  
  
LIST OF APPENDICES 
 Appendix 1
 Actelion guidelines for RHC  .........................................................................98  
Appendix 2  Actelion guidelines for 6MWT  ...................................................................100  
[STUDY_ID_REMOVED]
Appendix 3  Borg dyspnea index .....................................................................................105  
Appendix 4  WHO Functional Classification of pulmonary hypertension ......................106  
Appendix 5  Central laboratory alert thresholds ..............................................................106  
  
[STUDY_ID_REMOVED]
LIST OF ABBREVIATIONS AND ACRONYMS 
6MWD  6-minute walk distance  
6MWT  6-minute walk test 
AE  Adverse event  
ALT   Alanine aminotransferase  
ANCOVA   Analysis of covariance  
AST   Aspartate aminotransferase 
ATS   American Thoracic Society  
BMI   Body mass index  
BP  Blood pressure  
CEC   Clinical Events Committee  
CFR   Code of Federal Regulations  
cGMP   Cyclic guanosine monophosphate 
CI  Confidence interval  
CL  Confidence limit  
CO  Cardiac output 
CRA   Clinical Research Associate  
CRF   Case Report Form  
CRO   Contract Research Organization  
CYP3A4   Cytochrome P450 3A4  
DL CO  Diffusing capacity of the lung for carbon monoxide 
d/sSAP   Diastolic/systolic systemic arterial pressure  
ECG   Electrocardiogram  
eCRF   Electronic case report form  
EMA   European Medicines  Agency  
EOMOP   End of main observation period 
EOS   End of study 
EOT   End of treatment 
ERA   Endothelin receptor antagonist  
FAS  Full Analysis Set  
FC  Functional c lass 
[STUDY_ID_REMOVED]
FDA   Food and Drug Administration 
FEV 1  Forced expiratory volume in 1 second 
FVC   Forced vital capacity  
GCP   Good Clinical Practice  
GMR   Geometric mean ratio  
HIV  Human immunodeficiency virus 
HR  Heart rate  
IB  Investigator’ s Brochure  
ICF  Informed Consent Form  
ICH  International Council for Harmonis ation  
IDMC   Independent Data  Monitoring Committee  
IEC  Independent Ethics Committee 
ILSDRB   Independent Liver Safety Data Review Board  
IRB  Institutional Review Board  
IRT  Interactive Response Technology 
ISF  Investigator Site File  
LVEDP   Left ventricular end-diastolic pressure 
MedDRA   Medical Dictionary for Regulatory Activities  
m/d/sPAP   Mean/diastolic/systolic pulmonary artery pressure  
mRAP   Mean right atrial pressure 
MTD   Maximum tolerated dose  
NAION   Non-arteritic ischemic optic neuropathy  
NT-proBNP   N-terminal pro B-type natriuretic peptide  
PAH   Pulmonary arterial hypertension  
PAWP   Pulmonary arterial wedge pressure  
PDE -5  Phosphodiesterase-5 
PDE -5i  Phosphodiesterase-5 inhibitor 
PH  Pulmonary hypertension  
PI  Principal investigator  
PPS  Per-protocol Set 
PVOD  Pulmonary veno- occlusive disease  
[STUDY_ID_REMOVED]
PVR   Pulmonary vascular resistance  
RHC   Right heart catheterization  
SAC   Statistical Analysis Center  
SAE   Serious adverse event  
SAP  Statistical Analysis Plan  
SBP  Systolic blood pressure 
SC  Steering Committee  
SD  Standard deviation 
SIV  Site initiation visit  
SmPC   Summary of Product Characteristics  
SOC   System organ class  
SOP  Standard O perating P rocedure  
SUSAR   Suspected unexpected serious adverse reaction  
ULN   Upper limit of the normal range  
USPI   US package insert  
VO 2  Volume of oxygen uptake 
WHO  World Health Organization  
WU  Wood Units  
  
[STUDY_ID_REMOVED]
PROTOCOL SYNOPSIS AC-065A308 
TITLE  The efficacy and safety of initial triple versus initial dual oral 
combination therapy in patients with newly diagnosed pulmonary arterial hypertension: A multi- center, double -blind, placebo-
controlled, Phase 3b study 
ACRONYM  TRITON  
OBJECTIVES  Primary objective  
To compare the effect on pulmonary vascular resistance ( PVR ) of an 
initial triple oral regimen (macitentan, tadalafil, selexipag) versus a n 
initial dual oral regimen (macitentan, tadalafil, placebo ) in newly 
diagnosed, treatment -naïve subjects with pulmonary arterial 
hypertension ( PAH).  
Secondary objectives  
To compare an initia l triple oral regimen (macitentan, tadalafil, 
selexipag) with a n initial dual oral regimen (macitentan, tadalafil, 
placebo ) in newly diagnosed, treatment -naïve subjects with PAH, with 
respect to cardio -pulmonary hemodynamics (other than PVR), 
exercise capacity, disease severity, disease progression events , safety, 
and tolerability.  
Exploratory objectives  
To compare an initial triple oral regimen (macitentan, tadalafil, 
selexipag) with a n initial dual oral regimen (macitentan, tadalafil, 
placebo ) in newly diagnosed, treatment -naïve subjects with PAH, with 
respect to additional disease severity endpoints.  
DESIGN  This is a prospective, multi -center, double -blind, randomized, 
placebo -controlled, parallel group, P hase 3b, efficacy and safety study 
comparing a triple oral regimen (macitentan, tadalafil, selexipag) with a dual oral regimen (macitentan, tadalafil, placebo ) 
in newly 
diagnosed, treatment-naïve subjects with PAH.  
       
[STUDY_ID_REMOVED]
PERIODS  
 
1 Signed written informed consent is required prior to any study- mandated procedure  (right heart 
catheterization [ RHC ] data obtained at the study site before informed consent signature but 
within 28 days prior to Day 1 are acceptable).  
2 Increase in tadalafil dose on Day 8 ± 3.  
3 For simplification, most  visits between Day 1 and end of main observation period ( EOMOP ; 
as defined below) are not displayed. The complete visits and assessments are shown in  Table 1.  
4 If double -blind treatment (selexipag/placebo) is discontinued before Week 26: The Week 26 
assessments should be done either at Week 26 or before start of rescue therapy (prostacyclin, 
prostacyclin analog, or prostacyclin receptor agonist), whichever is first.  
5 The EOMOP is the data cutoff for the main efficacy and safety analyses, followed by data 
cleaning and unblinding of the treatment group allocation. The EOMOP visit is planned 
26 ± 1 weeks after enrollment of the last subject. This time point will be announced by Actelion 
approximately 6  months in advance. The EOMOP v isit is not required if within ± 2 weeks of a 
patient ’s Week 26 visit or Month 12, 18, 24, 30, etc. visit.  
6 All 3 study treatments are provided until the e nd of treatment ( EOT ) visit, which is planned 
approximately 4 months after the EOMOP visit. In order to allow sufficient time for the 
investigator to arrange any post- study therapy, Actelion will announce EOT approximately 
10 months in advance, and unblind  the treatment group allocation (selexipag or placebo) 
approximately 1 month prior to EOT. In case of premature discontinuation of all 3 study 
treatments, the EOT visit should be performed within 1 week but the subject  should be followed 
up according to the schedule of assessments until end of study ( EOS ; as defined below).  
7 EOS is defined as the last data collection for a subject. The EOS visit for all subjects (regardless 
of whether they are receivin g 3, 2, 1, or no study treatment) is planned approximately 5 months 
after the EOMOP visit . For all randomized patients, follow -up for disease progression 
(including death) will continue until  EOS.  
[STUDY_ID_REMOVED]
PLANNED DURATION The study duration will be approximately 4 years , based on an 
assumed enrollment period of 3 years . 
SITE(S)  / 
COUNTRY(IES)  The study will be conducted  at approximately 75 sites in 
approximately 20 countries.  
SUBJECTS / 
GROUPS  Approximately 238 subjects will be randomized in a 1:1 ratio to the 
two treatment groups (approximately 119 subjects per group), 
stratified by region (North America  versus rest of world ) and WHO 
functional c lass (FC)  at baseline (I/II versus III/IV) . 
INCLUSION CRITERIA
 1. Signed informed consent prior to any study -mandated procedure.  
2. Male or female ≥ 18 and ≤ 75 years of age at screening.  
3. Initial PAH diagnosis < 6 months prior to Day 1.  
4. RHC performed between Day −28 and Day 1 (RHC data obtained 
at the study site within this time frame, but before the study, 
i.e., before signed informed consent, are acceptable), meeting all the following criteria:  
• Mean pulmonary artery pressure ( mPAP ) ≥ 25 mmHg.  
• Pulmonary artery wedge pressure  or left ventricular 
end-diastolic pressure ≤ 15 mmHg.  
• PVR ≥ 480 dyn·sec/cm5 (≥ 6 Wood U nits).  
• Negative vasoreactivity test mandatory in idiopathic , heritable, 
and drug/toxin induced PAH (at this or a previous RHC).  
5. Symptomatic PAH belonging to one of the following subgroups:  • Idiopathic. 
• Heritable.  
• Drug or toxin induced. 
• Associated with one of the following: - Connective tissue disease.  
- HIV infection. - Congenital heart disease with simple systemic -to-pulmonary 
shunt (atrial septal defect, ventricular septal defect, patent ductus arteriosus) ≥ 1 year after surgical repai r.  
6. 6-minute walk distance ( 6MWD) ≥ 50 m at screening.  
7. Women of childbearing potential must:  
• Have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at the Day 1 visit, and  
• Agree to perform monthly pregnancy tests up to EOS, and 
• Agree to use reliable contr aception  from screening up to 
1 month following discontinuation of the last study treatment . 
[STUDY_ID_REMOVED]
Reliable contraception must be started at least 11 days prior to Day 1.  
EXCLUSION  
CRITERIA  1. Any PAH -specific drug therapy (e.g., any endothelin receptor 
antagonist [ERA] , phosphodiesterase- 5 inhibitor ( PDE -5i), 
soluble guanylate cyclase stimulator, prostacyclin, prostacyclin 
analog, or prostacyclin receptor agonist)  at any time prior to 
Day 1 (administration for vasoreactivit y testing is permitted; 
previous PAH- specific drugs used intermittently for the 
treatment of digital ulcers or Raynaud ’s phenomenon are 
permitted if stopped > 6 months prior to Day 1).  
2. Cardio -pulmonary rehabilitation program based on exercise 
(planned, or started ≤ 12 weeks prior to Day 1).  
3. Body mass index (BMI) > 40 kg/m2 at screening.  
4. Presence of three or more of the following risk factors for heart failure with preserved ejection fraction  at screening:  
• BMI > 30 kg/m
2. 
• Diabetes mellitus of any type.  
• Essential hypertension. 
• Coronary artery disease, i.e., any of the following:  - History of stable angina or 
- More than 50% stenosis in a coronary artery (by coronary angiography) or  
- History of myocardial infarction or  
- History of or planned coronary artery bypass grafting 
and/or coronary artery stenting. 
5. Acute myocardial infarction ≤ 12 weeks prior to screening.  
6. Cerebrovascular events (e.g., transient ischemic attack, stroke)  
≤ 12 weeks prior to screening. 
7. Known permanent atrial fibrillation.  
8. Systolic blood pressure < 90 mmHg at screening or Day 1. 
9. Ongoing or planned treatment with organic nitrates and/or 
doxazosin. 
10. Presence of one or more of the following signs of relevant lung disease at any time up to screening:  
• Diffusing capacity of the lung for carbon monoxide ( DL CO) 
< 40% of predicted UNLESS  computed tomography  reveals 
no or mild interstitial lung disease.  
• Forced vital capacity ( FVC ) < 60% of predicted.  
[STUDY_ID_REMOVED]
• Forced expiratory volume in one second (FEV1) < 60% of 
predicted.  
Pulmonary function tests may be performed either with or 
without the use of bronchodilators, as per local clinical practice. 
11. Known or suspected pulmonary veno- occlusive disease.   
12. Documented severe hepatic impairment (with or with out 
cirrhosis) according to National Cancer Institute organ 
dysfunction working group criteria, defined as total bilirubin 
> 3 × upper limit of the normal range  (ULN ) accompanied by 
aspartate aminotransferase ( AST ) > ULN (assessed at screening); 
and/or Child-Pugh Class C.  
13. Serum AST and/or alanine aminotransferase (ALT)  > 3 × ULN 
(assessed at screening).  
14. Severe renal impairment (estimated creatinine clearance 
≤ 30 mL/min/1.73 m2) assessed at screening.  
15. Ongoing or planned dialysis. 
16. Hemoglobin < 100 g/L assessed at screening. 
17. Known or suspected uncontrolled thyroid disease (hypo- or hyperthyroidism).  
18. Loss of vision in one or both eyes because of non- arteritic 
ischemic optic neuropathy. 
19. Treatment with strong inducers  of cytochrome P450 3A4 
(CYP3A4 ) (e.g., carbamazepine, rifampin, rifampicin, rifabutin, 
rifapentin, phenobarbital, phenytoin, and St. John’ s wort) 
≤ 28 days prior to Day 1.  
20. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, 
itraconazole, voriconazole, clarithromycin, telithromycin, 
nefazodone, ritonavir, and saquinavir) and/or strong inhibitors of CYP2C8 (e.g., gemfibrozil) ≤ 28 days prior to Day 1.  
21. Treatment wi th another investigational drug (planned, or taken 
≤ 12 weeks prior to Day 1 ). 
22. Hypersensitivity to any of the 3 study treatments or any excipient of their formulations 
(lactose, magnesium stearate, 
microcrystalline cellulose, hydroxypropyl cellulose, povidone, corn starch, sodium starch glycolate type A, polyvinyl alcohol, 
polysorbate 80, titanium dioxide, talc, xanthan gum, lecithin 
from soya, croscarmellose sodium, hypromellose, sodium 
laurylsulfate, triacetin, iron oxide yellow, iron oxide red, iron 
oxide black, d -mannitol, propylene glycol, carnauba wax) .  
[STUDY_ID_REMOVED]
23. Pregnancy, breastfeeding, or intention to become pregnant during the study.  
24. Concomitant life -threatening disease with a life expectancy 
< 12 months. 
25. Alcohol abuse. 
26. Any factor or condition likely to affect protocol compliance of the subject, as judged by the investigator.  
STUDY TREATMENTS Investigational treatment  
• Macitentan, open -label, oral tablet, 10 mg once daily (preferably 
always in the morning or always in the evening; to be recorded in the electronic Case Report Form  [eCRF ]).  
• Tadalafil, open -label, oral tablet, 20 mg one or two tablets once 
daily ( preferably always in the morning or always in the evening ; 
to be recorded in the eCRF ).  
• Selexipag  oral tablet , 200 µg, one to eight tablets twice daily (in 
the morning and in the evening). A once -daily regimen is 
recommended in patients with moderate hepatic impairment 
(Child -Pugh class B) due to the increased exposure to selexipag 
and its active metabolite.  
Comparator treatment  
• Macitentan, open -label, oral tablet, 10 mg once daily (preferably 
always in the morning or always in the evening ; to be recorded in 
the eCRF ).  
• Tadalafil, open -label, oral tablet, 20 mg one or two tablets once 
daily ( preferably always in the morning or always in the evening ; 
to be recorded in the eCRF ).  
• Matching placebo to selexipag  oral tablet , 200 µg, one to eight 
tablets twice daily (in the morning and in the evening). A once-
daily regimen is recommended in patients with moderate 
hepatic impairment (Child -Pugh class B) due to the increased 
exposure to selexipag and its active metabolite.  
[STUDY_ID_REMOVED]
CONCOMITANT THERAPY  Forbidden concomitant therapy:  
• Any PAH- specific drug ( e.g., ERA , PDE -5i [also if used for 
erectile dysfunction] , soluble guanylate cyclase stimulator, 
prostacyclin, prostacyclin analog, or prostacyclin receptor agonist)  
other than the 3 study treatments  up to EOT , except if used as 
rescue therapy . If another PAH -specific drug is started (and the 
corresponding study  treatment is stopped), subjects remain in the 
study, irrespective of whether they are receiving 3, 2, 1, or no study treatments.  
• Organic nitrates (other medications with vasodilatory effects must be used with caution).  
• Doxazosin. 
• Strong inducers of CYP3 A4 (e.g., carbamazepine, rifampin, 
rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and 
St. John’ s wort) during treatment with macitentan and/or tadalafil. 
• Strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, 
voriconazole, clarithromy cin, telithromycin, nefazodone, 
ritonavir, and saquinavir)  during treatment with macitentan and/or 
tadalafil . 
• Strong inhibitors of CYP2C8 (e.g., gemfibrozil) during treatment with selexipag/placebo.  
• Any investigational drug other than the 3 study treatments.  
• Cardio -pulmonary rehabilitation programs  based on exercise 
between Screening  and the Week 26 visit. 
ENDPOINTS Primary efficacy endpoint  
The primary endpoint is the ratio of Week 26 to baseline PVR.  Secondary efficacy endpoints  
1. Change in 6MWD from baseline to Week 26. 
2. Change in N -terminal pro B -type natriuretic peptide (NT -proBNP) 
from baseline to Week 26 . 
3. Absence of worsening  in WHO FC from baseline to Week 26. 
4. Change in RHC variables other than PVR (mPAP, cardiac index, 
total pulmonary resistance , mean right atrial pressure, venous 
oxygen saturation) from baseline to Week 26. 
5. Time from randomization to the first disease progression  event up 
to EOMOP  + 7 days  (adjudicated by the Clinical Events 
Committee  [CEC ]), defined as any of the following:  
a. Death (all causes; adjudicated for PAH relationship).  
b. Hospitalization for worsening PAH.  
[STUDY_ID_REMOVED]
c. Initiation of prostacyclin, a prostacyclin analog, or a prostacyclin receptor agonist for worsening PAH.  
d. Clinical worsening  defined as a post -baseline decrease in 
6MWD by > 15% from the highest 6MWD obtained at or after baseline, accompanied by WHO FC  III or IV (both 
conditions confirmed at two consecutive pos t-baseline 
visits separated by 1 –21 days).  
 Safety endpoints  
• Treatment -emergent adverse events (AEs).  
• AEs leading to premature discontinuation of any of the 3 study 
treatments.  
• Treatment -emergent serious AEs.  
• Treatment -emergent deaths.  
• Treatment -emergent marked lab oratory abnormalities.  
• Change from baseline in laboratory variables . 
• Change from baseline in vital signs.  
ASSESSMENTS See Table 1.  
STATISTICAL METHOD -
OLOGY  Analysis sets:  
The Safety S et includes all subjects who received at least one dose of 
any of the 3 study treatments . 
The Full Analysis Set (FAS) includes all randomized subjects . 
The Modified Full Analysis Set (Modified FAS) includes all subjects from the FAS who received at least one dose of each of the 3 study treatments.  
The Per -protocol S et includes all subjects  from the FAS who received 
at least one dose of double -blind study treatment  and who have no 
major protocol deviation. Primary endpoint:  
The primary efficacy endpoint is the ratio of Week 26 to baseline PVR. A 
geometric mean ratio (GMR) of Week 26 to baseline 
PVR  < 1 corresponds to a reduction in PVR from baseline.  
Statistical hypotheses: 
The null hypothesis is that the GMR of Week 26 to baseline PVR is 
equal in the dual and triple therapy groups. The alternative hypothesis 
[STUDY_ID_REMOVED]
is that these GMRs are different, with a difference of –0.223 expressed on a log scale.  
Type I and II errors and power:  
The overall type I error (α) is set to 0.05 (two -sided). The type II error 
is set to 0.10 and therefore the power to 90%. Primary analysis: 
Following the intent- to-treat principle , the primary analysis will be 
conducted on the FAS. 
The ratio of Week 26 to baseline PVR will be log- transformed (base 
e) and analyzed using an analysis of covariance with factors for 
treatment group, region (as stratified at randomization), WHO FC (as stratified) and a continuous 
covariate for baseline log PVR. The 
treatment group difference (on log -scale) and its 95% confidence 
interval (CI) will be estimated based on the model.  
The triple versus dual ratio of GMRs and its 95% CI will be obtained by exponenti ation. The null hypothesis will be rejected if the 95% CI 
around the ratio of the GMR s excludes 1.  
For subjects  with a post -baseline PVR measurement obtained before 
Week 26, the (last) post -baseline PVR measurement will be carried 
forward. For subjects without a post -baseline PVR measurement, the 
baseline PVR will be carried forward (i.e., the ratio of Week 26 to baseline is set to one). 
Subjects with missing baseline PVR 
measurement will be excluded from analysis.  
Secondary analyses: 
To control for multiplicity across the primary and selected secondary  
efficacy endpoints, statistical analyses will be performed in the 
following sequence: change from baseline to Week 26 in 6MWD,  
change from baseline to Week 26 in NT -proBNP , time from 
randomization to first disease progression event , and a bsence of 
worsening from baseline to Week 26 in WHO FC . The changes from 
baseline to Week  26 in other RHC variables will be excluded from 
this hierarchical testing strategy as they include too many variables . 
Secondary efficacy variables will be analyzed for the FAS at α = 0.05 
(two-sided) using 95% CIs. 
Safety analysis:  
[STUDY_ID_REMOVED]
All safety analyses will be performed on the Safety Set using descriptive statistics. Additional safety analyses will be performed for  
the subset of subject s who received at least one dose of double -blind 
study treatment. 
Interim analysis:  
This study uses a group sequential design, and one interim analysis is 
planned when 33% of planned enrolled subjects in each arm have 
completed their Week 26 assessment or prematurely discontinued the study.  
This interim analysis is intended to test for futility  (non-binding) , in 
order to prevent continuing treating subjects with triple combination therapy if it is unlikely to show a clinical benefit f or the subjects.  
However, as the interim analysis is designed to  assess the efficacy of 
the triple v ersus the d ual combination, it is not considering all safety 
aspects. Thus , an Independent Data Monitorin g Committee ( IDMC ) 
will review efficacy, safety and tolerability data at regular intervals 
prior to and after the interim analysis.  
Sample size calculations:  
An integrated analysis of two bosentan studies (BENEFIT, 
AC-052- 366, and EARLY, AC -052- 364) and one macitentan stud y 
(the hemodynamic sub- study of SERAPHIN, AC -055- 302) suggested 
that the within group standard deviation (SD) of the log- transformed 
ratio of Week 26 to baseline PVR is 0.41 (90% CI: 0.39–0.43). This is in line with published PVR data from studies of dual 
or triple 
combination therapy. For this trial, a more conservative SD  = 0.5 on 
the log- scale was assumed.  
Four studies of initial dual therapy reported reductions  (calculated)  of 
PVR from baseline of 40% (n = 22; 95% CI: 27% –50%), 51% 
(n = 23; 95% CI: 42% –58%), 45% (n  = 52; 95% CI: 38% –51%), and 
54% (n=16; 95% CI: 48%–60%). 
One observational study of initial triple therapy reported a reduction 
(calculated) of PVR of 68% (n  = 18; 95% CI: 62%–74%).  
Assuming 50% PVR reduction in the dual therapy group, 60 % 
reduction in the triple therapy group (corresponding to a ratio of 
geometric means of 0.80, i.e., 20% difference in favor of triple 
therapy) , and an overall type I error level of 5%, around 238 subject s 
[STUDY_ID_REMOVED]
would provide an overall 90% power at final analysis using a group sequential design and Pocock boundary , with interim analysis 
performed  when 33% (i.e., 79 subjects ) have completed the Week 26 
PVR assessment . 
STUDY COMMITTEES  • Steering Committee.  
• CEC.  
• IDMC.  
• Independent Liver Safety Data Review Board .  
[STUDY_ID_REMOVED]
Table 1 Visit and assessment schedule  
PERIODS  Name  SCREE
-NING  TREATMENT FOLLOW -
UP 
 Duration  28 days   30 days  
VISITS  Name  Scree-ning 
6 Random -
ization        End of main observation period 
(EOMOP) 5,14 End of 
Treatment 
(EOT) 5 Unscheduled 
visits 1, 2, etc 
3, 15  End of 
Study 
(EOS) 1, 5 
 Time  Day −28 
to Day 1  Day 1 Day 8 ( ± 
3 days) 1 Day 15  
(± 3 
days)  Weekly phone calls 
2 Week 12 
(
± 1 
week)  Week 26 
(
± 1 
week)  Month 12, 
18, 24, 30, 
etc 
(± 2 
weeks)  13 Will be announced 
11 Will be 
announced 
11 Any time 
between Day 
1 and EOS 3 30–35 days 
after EOT 
1,5 
Informed consent 10 X            
Eligibility  & demographics  X            
Medical history  X            
Right heart catheterization  X 10      X    X  
Physical examination  X   X  X X X X X X  
Vital signs (BP, HR)  X X 7  X  X X X X X X  
WHO FC 15 X X 7    X X X X X X  
6MWD  15, Borg dysp . index  X X 7    X X X X X X  
Laboratory tests general  17 X 16 X 7    X X X X X X  
Liver and hemoglobin tests 9 X 16 X 7 Monthly  13 (± 1 week)  X X  
Pregnancy test 8 X X Monthly  13 (± 1 week)  X X X 
Contraceptive methods docu  X 4 X  X  X X X X X X X 
Blood sampling biomarkers  X      X      
Study treatm. dispensing   X  X  X X X X  X  
Study treatment return       X X X X X X  
Previous/concom. therapies  X X  X  X X X X X X  
AEs, SAEs 12 X X X X X X X X X X X X 
[STUDY_ID_REMOVED]
1 Visit or phone call.  
2 Weekly phone calls during the up-titration phase of double -blind study treatment.  
3 Unscheduled visits may be performed at any time during the study and may include any  of the indicated assessments, based on investigator judgment.  
4 Reliable contraception must be started at least 11 days prior to Day 1.  
5 EOMOP, EOT, EOS : See definitions under ‘Periods ’ above.  
6 It is permitted to re -screen subjects once, if the reason for non -eligibility was transient (e.g., abnormal laboratory test, insufficient wash -out period of a 
forbidden medication). All screening assessments should then be repeated at the time of re -screen ing.  
7 Only needed if screening assessment > 7  days before Day 1.  
8 In women of childbearing potential only . Serum pregnancy test s at Screening, Week 12, Week 26 , monthly (± 1 week) throughout the study , at 
EOMOP, EOT, and if pregnancy is suspected at an y time during the study . Urine pregnancy test s at the Day 1 visit and if  a monthly  serum test is 
missed . At EOS either serum or urine pregnancy testing.  
9 Monthly (± 1 week)  central lab oratory  testing of liver aminotransferases , total and direct bilirubin,  and hemoglobin is mandatory throughout the 
study . For monthly testing , blood drawing is performed either at the study site, at a satellite  laboratory  close to where the subject lives , or by a 
phlebotomy service  at the subject’s home .  
10 Signed informed consent required b efore any study -mandated procedure.  However, RHC data obtained at the study site within 28 days prior to Day 1 
but before the study (i.e., before signed informed consent) are acceptable.  
11 Actelion will announce EOMOP approximately 6 mo nths in advance and EOT approximately 10 months in advance. The treatment group allocation 
(unblinding) will be disclosed approximately 1 month prior to EOT.  
12 All AEs and SAEs that occur after signing the Informed Consent Form and up to 30 days after discontinuation of the last of the 3 study treatments 
must be reported.  
13 For this clinical trial, a month is defined as 30 days.  
14 The EOMOP visit is not requ ired if within ±  2 weeks of a  patient ’s Week 26 visit or Month 12, 18, 24, 30, etc . visit.  
15 If any post -baseline decrease in 6MWD by > 15% from the highest 6MWD obtained at or after screening  is observed , accompanied by WHO FC III or 
IV, then both the 6MWD and WHO FC must be reassessed  at an unscheduled visit after 1– 21 days .  
16 As an alternative to central laboratory tests , eligibility of subjects at Screening may be determined using local laboratory tests as long as the central 
laboratory kit is used in parallel.  All local laboratory data including the normal ranges must be entered on dedicated eCRF pages.  
17 Laboratory tests general: Hematology, clinical chemistry  including liver and hemoglobin tests, coagulation tests, and NT -proBNP.  
 6MWD = 6 -minute walk distance; AE = adverse event; BP = blood pressure;  eCRF = electronic case report form;  EOMOP  = end of main observation 
period; EOS = end of st udy; EOT = end of tr eatment; FC = functional class; HR = heart rate;  NT-proBNP = N-terminal prohormone  of brain 
natriuretic peptide ; RHC = right heart catheterization; SAE = serious adverse event; WHO = World Health Organization.   
 
[STUDY_ID_REMOVED]
PROTOCOL 
1 BACKGROUND 
1.1 Indication 
Pulmonary arterial hypertension (PAH) is a serious chronic disorder of the pulmonary circulation of diverse etiology and pathogenesis . PAH is  characterized by a progressiv e 
increase in pulmonary artery  pressure (PAP) and in pulmonary vascular resistance (PVR) 
potentially leading to right heart failure and death [ Benza 2010, Kylhammar 2014, 
Oudiz 2013]. The complex pathogenesis of PAH involves dysfunction of three key 
pathways: the endothelin pathway, the nitric oxide pathway, and the prostacyclin pathway [Humbert 2004].  
PAH is hemodynamically defined as a resting mean pulmonary artery  pressure (mPAP) of 
at least  25 mmHg with normal pulmonary artery wedge pressure (PAWP) (or left 
ventricular end -diastolic pressure [LVEDP]) of 15 mmHg or less, and a PVR greater than 
3 Wood Units (WU) [ Hoeper 2013].   
The updated clinical classification of pulmonary hypertension (PH; Nice 2013) [Simonneau 2013] classifies the numerous conditions that are known to lead or be 
associated with the development of PAH into 4 groups, based on their similar clinical presentation, pathology, pathophysiology, prognosis and, most of all, similar therapeutic approach. PAH may occur in the absence of a demonstrable cause (idiopathic), in a familial setting (heritable), as the result of the use of certain drugs and toxins, or it can be associated 
with a connective tissue disease, HIV infection, portal hypertension, congenital  heart 
disease, or schistosomiasis.  
1.2 Study treatment s 
Three PAH -specific drugs are used as s tudy treatments in this trial: macitentan , tadalafil, 
and selexipag . Macitentan  is an endothelin receptor antagonist (ERA) and acts via the 
endothelin pathway, tadalafil is a phosphodiesterase type 5 (PDE -5) inhibitor and acts via 
the nitric oxide pathway, and selexipag is an prostacyclin  receptor agonist and acts via the 
prostacyclin pathway, i.e., when administered together , these drugs tackle all three key 
PAH the rapeutical pathways mentioned in Section  1.1.  
1.2.1 Macitentan  
Macitentan is approved in the US, the Europe an Union, and an increasing number of other 
countries for the treatment of PAH.  More detailed information on macitentan can be found in the Investigator’s Brochure  (IB) 
[Macitentan IB ].  
[STUDY_ID_REMOVED]
1.2.1.1 Nonclinical results  
Macitentan i s an orally active, non- peptide, potent dual endothelin receptor  A and B  
antagonist. Macitentan showed dose dependent efficacy in nonclinical models of hypertension and PH. In nonclinical safety studies, no effects on normal physiological functions or ECG variables, including cardiac repolarization, were observed, with the exception of a decrease in arterial blood pressure (BP) observed in a cardiovascular study 
in dogs. Macitentan has no genotoxic and no carcinogenic potential. In the pivotal 26- week 
and 39- week toxicity studies, the exposures in animals at the no -observed -adverse- effect 
levels were above the anticipated clinical exposures and provided a margin of safety for studies in humans. Reproductive toxicity studies showed that macitentan is teratoge nic 
without affecting male or female fertility. Teratogenicity is considered to be an ERA class effect.  
1.2.1.2 Clinical pharmacology 
During the Phase 1 program, more than 200 healthy subjects and about 30 subjects with 
renal and hepatic impairment were treated with macitentan. Macitentan was well tolerated in all studies. The most frequently reported adverse event (AE) was headache.  1.2.1.3 Clinical efficacy  
Efficacy  was established in a long -term study in PAH patients with predominantly WHO 
functional c lass (FC) II –III symptoms treated for an average of 2 years [ Pulido 2013]. 
Patients had idiopathic or heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%) , and were 
treated with macitentan monothe rapy or in combination with PDE -5 inhibitors ( PDE -5i) or 
inhaled prostanoids.  The trial demonstrated that macitentan 10 mg reduces the risk of morbidity/mortality in patients with symptomatic PAH, with a hazard ratio versus placebo of  0.55, 97.5% 
confidence limits (CLs) : 0.32, 0.76, p < 0.001. This represents a risk reduction of 45% 
[Pulido 2013]. The effect of macitentan was observed regardless of whether the patient was 
receiving other therapy for PAH.  The placebo -corrected mean change in 6 -minute walk distance (6MWD) from baseline to 
Month 6 showed an increase of 22.0 m (97.5% CLs : 3.2, 40.8) with macitentan 10 mg . The 
WHO FC  improved from baseline to Month 6 in 13% of the patients in the placebo group, 
as compared with 22% of those in the group that received 10 mg of macitentan (P  = 0.006) 
[Pulido 2013].  
A hemodynamic sub -study showed a placebo -corrected mean reduction of PV R from 
baseline to Month 6 of 38.5%  (97.5% CLs: 25.7, 49.0) with macitentan 10 mg 
[Pulido 2013].  
[STUDY_ID_REMOVED]
1.2.1.4 Summary of safety profile 
The safety of macitentan has been evaluated in a long -term placebo -controlled trial of 742 
patients with symptomatic PAH  [Pulido 2013, Macitentan IB ]. The mean treatment 
duration was 103.9 weeks in the macitentan 10 mg group, and 85.3 weeks in the placebo group. The most commonly reported adverse drug reactions are nasopharyngitis (14.0%), headache (13.6%), and anaemia (13.2%). The majority of adverse reactions are mild to 
moderate in int ensity. The overall incidence of treatment discontinuations because of 
adverse events was similar across macitentan 10 mg and placebo treatment groups (approximately 11%).  1.2.2 Tadalafil 
Tadalafil is approved in the US [ Adcirca USPI ], the European Union [ Adcirca SmPC ], and 
many other countries (see local prescribing information) for the treatment of PAH.  1.2.2.1 Nonclinical results  
Tadalafil is a selectiv e inhibitor of PDE -5, the enzyme responsible for the degradation of 
cGMP. PAH is associated with impaired release of nitric oxide by the vascular endothelium 
and consequent reduction of cGMP concentrations in the pulmonary vascular smooth muscle. PDE -5 is the predominant  phosphodiesterase in the pulmonary vasculat ure. 
Inhibition of PDE -5 by tadalafil increases the concentrations of cGMP resulting in 
relaxation of pulmonary vascular smooth muscle cells and vasodilation of the pulmonary vascular bed.  
Nonclinical s tudies have shown that the effect of tadalafil is mor e potent on PDE -5 than 
on other phosphodiesterases.  For the nonclinical toxicology of tadalafil see the prescribing information [ Adcirca SmPC , 
Adci rca USPI , local prescribing information ].  
1.2.2.2 Clinical pharmacology 
In clinical pharmacology studies, tadalafil (5 to 20 mg) was shown to potentiate the hypotensive effect of nitrates. Tadalafil must not be used in patients taking any form of organic nitrates.  
For other pharmacodynamics effects, interactions, and the pharmacokinetics of tadalafil see the SmPC and USPI  [Adcirca SmPC , Adcirca USPI , local prescribing information].  
1.2.2.3 Clinical efficacy  
Tadalafil was evaluated in a Phase 3 , randomized, double -blind, 16- week 
placebo -controlled study conducted in 405 patients with  PAH. Allowed background 
therapy included bosentan (maintenance dosing up to 125 mg twice daily). Subjects were randomly assigned to 1 of 5 treatment groups (tadalafil 2.5, 10, 20, 40 mg, or placebo) in 
[STUDY_ID_REMOVED]
a 1:1:1:1:1 ratio. The mean age of all subjects was 54 years (range 14–90 years) with the majority of subjects being Caucasian (81%) and female (78%). PAH etiologies were predominantly idiopathic PAH (61%) and related to collagen vascular disease (24%). More than half  (53%) of the subjects in the study were receiving concomitant bosentan therapy. 
The majority of subjects had a WHO F C III (65%) or II (32%). The mean baseline 6MWD  
was 343 meters. The primary efficacy endpoint was the change from baseline at  Week 16 
in 6M WD. In the tadalafil  40 mg treatment group, the plac ebo-adjusted mean increase in 
6MWD was 33 meters (95% confidence interval [ CI]: 15–50 meters; p = 0.0004). Placebo-
adjusted changes in 6MWD at 16 weeks were evaluated in subgroups. In patients taking only tadalafil 40 mg (i.e., without concomitant bosentan), the pl acebo -adjusted mean 
change in 6 MWD was 44 meters. In patients taking tadalafil 40 mg and concomitant 
bosentan therapy, the placebo adjusted mean change in 6MWD was 23 meters. There was less clinical worsening (defined as death, lung transplantation, atrial septostomy, hospitalization because of worsening PAH, initiation of new PAH therapy [ prostacyclin or 
prostacyclin analog, ERA , PDE -5i], or worsening WHO FC) in the tadalafil 40 mg group 
compared to the placebo group and the groups that used lower doses of tadalafil.  Patients (N  = 357) from the placebo- controlled study entered a non-controlled long- term 
extension study. Of these, 311 patients have been treat ed with tadalafil for at least 6  months 
and 182 for 1 year (median exposure 356 days; range 2 days to 415 days). The survival rate in the extension study was 96.5 per 100 patient years.  1.2.2.4 Summary of safety profile 
The most commonly reported adverse reactions, occurring in ≥ 10% of patients in the tadalafil 40 mg treatment arm, were headache, nausea, back pain, dyspeps ia, flushing, 
myalgia, nasophary ngitis and pain in extremity. The adverse reactions reported were 
transient, and generally mild or moderate. Adverse reaction data are limited in patients over 75 years of age. In the pivotal placebo- controlled study of tadalafil  for the treatment of 
PAH, a total of 323 patients were treated with tadalafil  at doses ranging from 2.5 mg to 40 
mg once daily and 82 pat ients were treated with placebo. The duration of treatment was 16 
weeks. The overall frequency of discontinuation due to AEs was low (tadalafil  11%, 
placebo 16%). Of the patients who completed the pivotal study, 357 entered a long- term 
extension study. Doses studied were 20 mg and 40 mg once daily.  1.2.3 Selexipag  
Selexipag  is approved for the treatment of PAH in the US, the European Union, and an 
increasing number of other countries. More detailed information on selexipag can be found in the IB [ Selexipag IB ].  
[STUDY_ID_REMOVED]
1.2.3.1 Nonclinical results  
Selexipag is an orally available non -prostanoid prostacyclin  receptor agonist. Whilst active 
by itself, selexipag is hydrolyzed to an active metabolite with prolonged terminal half -life 
and a high selectivity for the prostacyclin  receptor. Selexipag and its metabolite possess 
anti-fibrotic, anti -proliferative, and anti-thrombotic activity. Oral selexipag is effective in 
an animal model of PAH, improving hemodynamic and structural factors leading to increased survival. Selexipag seems to induce minimal or no tachyphylaxis in rats.  1.2.3.2 Clinical pharmacology 
For interactions as well as the pharmacodynamics and  pharmacokinetics of selexipag see 
the IB [ Selexipag IB ].  
1.2.3.3 Clinical efficacy  
In the multicenter, double -blind, placebo -controlled event -driven Phase 3 clinical trial 
GRIPHON, conducted in 1156 patients with PAH, selexipag demonstrated a clinically and statistically significant 40% risk reduction compared to placebo in the occurrence of a first morbidity/mortality event up to end of treatment (EOT) + 7 days (hazard ratio for selexipag versus placebo 0.60, 99%  CI: 0.46–0.78, 1- sided unstratified log -rank P  < 0.0001) . Results 
of all supportive analyses on the primary endpoint were consistent with that of the main analysis, and the observed treatment effect was also consistent across subgroups (PAH 
etiology, region, ethnicity, gender, age, WHO FC, and – most important in the setting of 
the present triple combination study – baseline PAH background medication) [ Sitbon 2015 , 
Selexipag IB ].  
The secondary endpoints of change from baseline to Week 26 in 6MWD measured at trough, and of time to first PAH -related death or hospitalization due to PAH , showed a 
statistically significa nt effect favoring selexipag over placebo. The secondary endpoints of 
absence of worsening in WHO FC from baseline to Week 26 and of time to death of all causes up to study closure did not show a difference between selexipag and placebo [Selexipag IB ].  
1.2.3.4 Summary of safety profile 
In the GRIPHON trial, patients were treated for up to 4.2 years. The most frequently 
reported AEs in the selexipag group were those associated wi th prostacyclin treatment: 
headache (65%  vs 32% in placebo group), diarrhea (42%  vs 18%), nausea (33%  vs 18% ), 
jaw pain (2 6% vs 6%), vomiting (18%  vs 9% ), pain in extremity (17% vs 8%), and myalgia 
(16% vs 6%). A total of 43.8% and 47.1% of patients in the  selexipag and placebo groups, 
respectively, had at least 1 serious adverse event  (SAE). The great majority of SAEs were 
consistent with the underlying PAH condition. PAH worsening and right ventricular failure were the most frequently reported SAEs, and both were reported at lower frequencies in the selexipag group (14.4% and 5.9%, respectively) compared to the placebo group (22.0% 
[STUDY_ID_REMOVED]
and 7.1%, respectively). A total of 31.7% of patients in the selexipag group and 37.1% in the placebo group had at least one AE leading to discontinuation of study treatment. Other than prostacyclin- associated AEs, most of the AEs that led to discontinuation of study 
treatment were SAEs associated with underlying PAH disease.   
Overall , in the GRIPHON study , the nature and incidence of typical 
prostacyclin -associated AEs (i.e., headache, flushing, diarrhea, nau sea, vomiting, jaw pain, 
myalgia and arthralgia) on selexipag was largely in line with that observed with prostacyclin and prostacyclin analogs  [Sitbon 2015, Selexipag IB ].  
Hypotension was reported more frequently in the selexipag group compared to the placebo group (5.9% and 3.8%, respectively). In the selexipag group 9.7% of patients had systolic 
blood pressure (SBP) ˂ 90 mmHg on at least one  occasion, compared to 6.7% in the 
placebo group. A decrease from baseline of > 40 mmHg in SBP was reported for 2.3% and 3.0% of patients in selexipag and placebo groups, respectively.  Bleeding was not observed more frequently in selexipag -treated patients compared to 
placebo, including in those patients treated concomitantly with anticoagulants. Anemia was reported more frequently in the selexipag group and a small reduction in hemoglobin was observed at most post- baseline visits.   
Hyperthyroidism was reported more frequently in the selexipag group compared to the placebo group. Corresponding laboratory changes were a small reduction in thyroid -stimulating hormone at most post -baseline visits. A po ssible association between 
thyroid disorders and PAH is described in the literature [reviewed i n Marvisi  2013]. 
Previously published investigations showed that prostaglandins may influence thyroid function by a direct effect on specific prostaglandin membrane receptors [ Chadha  2009].   
Importantly, in the GRIPHON study there were no additional safety and  tolerability 
findings in those patients receiving selexipag on top of both an ERA and a PDE -5i.  
1.3 Purpose and rationale of the study 
Recent  guidelines for the treatment of PAH [Galiè  2013] recommend ed sequential 
combination therapy in patients with an inadequate clinical response to initial monotherapy. However, b ased on the recent results of the AMBITION study 
[Galiè  2015a ], initial dual combination therapy with an ERA and a PDE -5i is emerging as 
a potential new standard of care in newly diagnosed PAH patients [ Galiè  2015b].  
To date , only one pilot study has investigated initial triple combination therapy 
[Sitbon 2014] , showing dramatic improvements in all relevant variables such as WHO  FC, 
6MWD, mPAP, cardiac index, and PVR. Although the study was small (n = 18), non-controlled, and used different drugs tha n in the present study (in particular, intravenous 
[STUDY_ID_REMOVED]
epoprostenol as the drug acting on the prostacyclin pathway ), it suggests that initial triple  
therapy in PAH may be beneficial  and safe.  
With the availability of selexipag , it is possible to inves tigate a  triple oral therapy  regimen. 
Data from the GRIPHON trial  suggest that selexipag is efficacious and safe irrespective of 
whether or not subjects  are already receiving ot her PAH drugs [ Sitbon 2015, Selexipag  IB]. 
In fact, the majority of the patient population in GRIPHON was prevalent and thus already being treated with an ERA and/or a PDE -5i at baseline.  
The above -mentioned triple therapy data from the GRIPHON trial [ Sitbon 2015, Selexipag 
IB] and the pilot study [ Sitbon 2014] provide a rationale for the present study.  The purpose 
is to investigate whether an initial triple oral treatment regimen combining an ERA , a 
PDE -5i, and selexipag  adds significant efficacy  benefit while being  safe and well tolerated , 
as compared to  an initial dual oral treatment regimen  with an ERA  and a PDE -5i 
[Galiè  2015a ].  
Given the extensive and long -term controlled efficacy and safety data available with all 
3 study treatments (including triple combination used in many subjects  in the GRIPHON 
study) and the careful follow -up of subjects mandated by this  protocol, the benefit/risk 
assessment supports the current study.  
2 STUDY OBJECTIVES 
2.1 Primary objective 
The primary objective of the study is to compare the effect on PVR of an initial triple oral regimen (macitentan,  tadalafil , selexipag ) versus an initial dual oral regimen ( macitentan , 
tadalafil , placebo) in newly diagnosed, treatment- naïve subject s with PAH.  
2.2 Secondary objectives 
The secondary objective of the study is to compare a n initial triple oral regimen  
(macitentan, tadalafil, selexipag ) with a n initial dual oral regimen (macitentan, tadalafil, 
placebo ) in newly diagnosed, treatment -naïve subjects  with PAH, with respect to 
cardio -pulmonary hemodynamics  (other than PVR) , exercise capacity, disease severit y, 
disease progression events , safety, and tolerability.  
2.3 Exploratory objectives 
The exploratory objective of the study is to compare a n initial triple oral regimen 
(macitentan, tadalafil, selexipag ) with a n initial dual oral regimen (macitentan, tadalafil, 
placebo ) in newly dia gnosed, treatment -naïve subjects  with PAH, with respect to  additional 
disease severity endpoints.  
[STUDY_ID_REMOVED]
3 OVERALL STUDY DESIGN AND PLAN 
3.1 Study design  
This is a prospective, multi -center, double -blind, randomized, placebo- controlled, parallel 
group, P hase 3b, efficacy and safety study comparing a triple oral regimen (macitentan, 
tadalafil , selexipag ) with a dual oral regimen (macitentan, tadalafil, place bo) in newly 
diagnosed, treatment- naïve subject s with PAH.  
This study uses  a group sequential design, with one interim analysis planned when 
approximately one thir d of the subjects have completed their Week 26 PVR assessment 
(primary endpoint) or prematurely discontinued the study.  Approximately 238 subject s will be randomized in a 1:1 ratio to the two treatment groups 
(approximately 119 subjects per group), stratified by region (North America versus rest of 
world ) and WHO FC at baseline (I/II versus  III/IV). The study will be conducted at 
approximately 75 sites in approximately 20 countries. Randomization will proceed until 
the required number of subject s has been reached. It will be competitive across 
participating sites. Actelion may replace sites with no subject  enrollment.  
The study periods at the subject  level are summarized in Figure 1. Figure 2 illustrates the 
planned duration of the study and the duration of the subject s’ participation in the study.  
[STUDY_ID_REMOVED]
Figure 1 Study periods ( subject  level)  
 
1 Signed written informed consent is required prior to any study -mandated procedure (right 
heart catheterization [RHC] data obtained at the study site before informed consent signature but within 28 days prior to Day 1 are acceptable).  
2 Study treatment initiation scheme: See Section  5.1.3.  
3 For simplification,  most visits between Day 1 and end of main observation period 
(EOMOP ; as defined below) are not displayed. The complete visits and assessments are 
shown in Table 1.  
4 If double -blind treatment (selexipag/placebo) is discontinued before Week 26: The Week 
26 assessments should be done either at Week 26 or before start of rescue therapy (prostacyclin, prostacyclin analog, or prostacyclin receptor agonist), whichever is first.  
5 The EOMOP is the data cutoff for the main ef ficacy and safety analyses, followed by data 
cleaning and unblinding of the treatment group allocation. The EOMOP visit is planned 26 ± 1 weeks after enrollment  of the last subject. This time point will be announced by Actelion 
approximately 6 months in advance. The EOMOP visit is not required if within ± 2 weeks of a patient ’s Week 26 visit or Month 12, 18, 24, 30, etc. visit.  
6 All 3 study treatments are provided until the EOT visit, which is planned approximately 
4 months after the EOMOP visit. In order to allow sufficient time for the investigator to arrange any post -study therapy, Actelion will announce EOT approximately 10 months in 
advance, and unblind the treatment group allocation (selexipag or placebo) approximately 1 month prior to EOT. In the event of  premature discontinuation of all 3 study treatments, 
the EOT visit should be performed within 1 week but the subject should be followed up according to the schedule of assessments until end of study ( EOS ; as defined below).  
7 EOS is defined as the last data collection for a subject. The EOS visit for all subjects 
(regardless of whether they are receiving 3, 2, 1, or no study treatment) is planned approximately 5 months after the EOMOP visit. For all randomized patients, follow -up for 
disease progression (including death) will continue until EOS . 
[STUDY_ID_REMOVED]
Figure 2 Planned duration (study level)  
 
 * See Figure 1 for abbreviations and definitions 
No sub-studies are planned.  
3.2 Study design rationale 
The rationale for the selected treatment groups is described in Section  1.3. The 
double- blind design is required to minimize any bias. Stratification by region and baseline 
WHO FC is justified by the fact that these variables  had a major impact on PVR (primary 
endpoint) in previous tr ials, in particular in the hemodynamic sub- study of Actelion ’s 
SERAPHIN trial (AC -055- 302) with macitentan .  
The use of a group sequential design is justified by the absence of prior data on the potential  
clinical benefit of a triple v ersus a dual oral combination therapy . The interim analysis is 
[STUDY_ID_REMOVED]
therefore designed as a futility analysis  to prevent continuing the trial and exposing subjects  
to unnecessary  burden if it is unlikely to demonstrate a relevant treatment difference.  
A maximum of 28 days for screening is considered an acceptable balance between granting sufficient time to conduct all assessments and not delaying treatment start for too long.  
Initiating  all 3 study treatment s within 2 wee ks is a pragmatic balance between a true initial 
triple therapy  approach and the need to carefully monitor subject  safety during this phase. 
The rules for up -titration of  selexipag [Section  5.1.3] are very similar to those used in the 
GRIPHON trial [ Sitbon 2015, Selexipag IB ].  
The primary endpoint (PVR) is determined at Week 26 because it is expected that during the first 26 weeks the 3 study treatments have sufficient time to exert a treatment effect.  
It is plann ed that Actelion will provide all 3 study treatments until approximately 
10 months after the last subject  has been enrolled  (EOT ). All subjects should continue the 
study until EOS, irrespective of whether they are receiving 3, 2, 1, or no study treatments  
up to EOT , and irrespective of any other PAH therapy administered . Consequently, the 
total study duration for a subject  will vary between approximately 11 months  and 
approximately 4 years , depending on the timepoint at which the subject  is enrolled and the  
enrollment rate  (assumed enrollment period is 3 years) . The reasons for keeping subject s 
in the study beyond Week 26 (primary endpoint) are (1) to allow  investigators to make 
informed decisions regarding  any post -study therapy  once the result of the prima ry analysis 
and study treatment allocation for each patient is  known (approximately 1 month prior to 
EOT ), (2) to assess some of the secondary and exploratory efficacy  and safety  endpoints 
requiring longer observation periods. One of the aims of this study  is to explore various 
disease severity and clinical outcome endpoints. A traditional clinical worsening endpoint does not appear feasible in a triple combination setting (too few events).  
3.3 Study committees 
The following study committees will be establishe d, each governed by a separate charter:  
o Steering C ommittee  (SC) - to advise on the study protocol, oversee the conduct of 
the study, contribute to interpretation of the results, and support publications.  
o Clinical Events Committee (CEC)  - to adjudicate the disease progression  events.  
o IDMC - to safeguard the interests of subject s by monitoring safety, tolerability, and 
efficacy data obtained in the study and making appropriate recommendations based on the reported data, thus ensuring that the study is being  conducted at  the highest 
scientific and ethical standards. The IDMC will be fully operational prior to enrollment of the first subject  into the study.  
[STUDY_ID_REMOVED]
o Independent Liver Safety Data Review Board (ILSDRB) - to provide advice 
regarding serious hepatic events of the study subject s. The ILSDRB is an external 
expert committee of hepatologists.  
4 SUBJECT POPULATION 
4.1 Subject population description 
The target population is subject s with PAH [ Simonn eau 2013] , as detailed in Sections 4.3 
and 4.4.  
4.2 Rationale for the selection of the study population 
The minimum PVR is 480 dyn·sec/cm5 (6 W U) in order  to exclude mild PAH in a study 
investigating an aggressive  treatment approach, i.e., initial triple therapy. Furthermore, 
with the change in PVR from baseline to Week 26 being the primary endpoint, subjects  
with an elevated baseline PVR may have a higher chance of a PVR improvement .  
The minimum 6MWD is  50 m in order to ensure a baseline value is  available, which is 
needed for several of the secondary and exploratory efficacy endpoints. This  avoids 
imputation of missing values in subject s who can hardly walk or not walk at all.  
The upper age limit is set to 75 years in order to exclude subject s with a potentially 
uncertain or atypical PAH diagnosis due to co-morbidities. For the same reason , subjects 
with conditions such as permanent atrial fibrillation, lung diseases indicative of PH 
etiologies other than PAH, and presence of multiple risk factors for  heart failure with 
preserved ejection fraction  are excluded.  
Exclusion of the remaining concomitant diseases and therapies  listed below is based on the 
prescribing information or other background information for  one or more of the 3 study 
treatments [ Macitentan IB , Adcirca SmPC , Adcirca USPI , and Selexipag IB ].  
4.3 Inclusion criteria 
For inclusion in the study, all of the following inclusion criteria must be fulfilled. It is not permitted to waive any  of the criteria for any subject :  
1. Signed informed consent prior to any study-mandated procedure. 
2. Male or female ≥ 18 and ≤ 75 years of age at screening.  
3. Initial PAH diagnosis < 6 months prior to Day 1.  
4. RHC performed between Day − 28 and Day 1 (RHC data obtained at the study site 
within this time frame, but before the study, i.e., before signed informed consent, are acceptable), meeting all the following criteria:  
• mPAP ≥ 25 mmHg. 
• PAWP or LVEDP ≤ 15 mmH g. 
[STUDY_ID_REMOVED]
• PVR ≥ 480 dyn·sec/cm5 (≥ 6 W U). 
• Negative vasoreactivity test mandatory in idiopathic , heritable, and drug/toxin 
induced PAH (at this or a previous RHC).  
5. Symptomatic PAH belonging to one of the following subgroups [ Simonneau 2013] :  
• Idiopathic. 
• Heritable.  
• Drug or toxin induced. 
• Associated with one of the following: − Connective tissue disease.  
− HIV infection. 
− Congenital heart disease with simple systemic -to-pulmonary shunt (atrial septal 
defect, ventricular septal defect, patent ductus arteriosus) ≥ 1 year after surgical repair.  
6. 6MWD ≥ 50 m at screening.  
7. Women of childbearing potential [defined in Section  4.5.1] must: 
• Have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at the Day 1 visit, and 
• Agree to perform monthly pregnancy tests up to EOS, and 
• Agree to use reliable contraception [defined in Section  4.5.2] from screening up to 
1 month following discontinuation of the last study treatment . Reliable 
contrac eption must be started at least 11 days prior to Day 1.  
4.4 Exclusion criteria 
Subjects must not fulfill any of the following exclusion criteria. It is not permitted to waive 
any of the criteria for any subject:   
1. Any PAH -specific drug therapy  (e.g., any ERA , PDE -5i, soluble guanylate cyclase 
stimulator, prostacyclin, prostacyclin analog, or prostacyclin receptor agonist ) at any 
time prior to Day 1 (administration for vasoreactivity testing  is permitted ; previous 
PAH- specific drugs  used intermittently for the treatment of digital ulcers or Raynaud ’s 
phenomenon are permitted if stopped > 6 months prior to Day  1).  
2. Cardio -pulmonary rehabilitation program based on exercise (planned, or started 
≤ 12 weeks prior to Day 1).  
3. Body mass index (BMI) > 40 kg/m2 at screening.  
4. Presence of three or more  of the following risk factors for heart failure with preserved 
ejection fraction  at screening:  
• BMI > 30 kg/m2. 
• Diabetes mellitus of any type.  
• Essential hypertension. 
• Coronary artery disease, i.e., any of the following:  
[STUDY_ID_REMOVED]
− History of stable angina or 
− More than 50% stenosis in a coronary artery (by coronary angiography) or 
− History of myocardial infarction or 
− History of or planned coronary artery bypass grafting and/or coronary artery stenting.   
5. Acute myocardial infarction ≤ 12 weeks prior to screening.  
6. Cerebrovascular events (e.g., transient ischemic attack, stroke)  ≤ 12 weeks prior to 
screening . 
7. Known permanent atrial fibrillation.  
8. SBP < 90 mmHg at screening or Day 1. 
9. Ongoing or planned treatment with organic nitrates and/or doxazosin. 
10. Presence of one or more  of the following signs of relevant lung disease at any time up 
to screening:  
• Diffusing capacity of the lung for carbon monoxide ( DL CO) < 40% of predicted 
UNLESS  computed tomography reveals no or mild interstitial lung disease . 
• Forced vital capacity ( FVC ) < 60% of predicted. 
• Forced expiratory volume in one second ( FEV 1) < 60% of predicted. 
Pulm onary function tests may be performed either with or without the u se of 
bronchodilators, as per local clinical practice.  
11. Known or suspected pulmonary veno- occlusive disease (PVOD).   
12. Documented severe hepatic impairment (with or without cirrhosis) according to National Cancer Institute organ dysfunction working group criteria, defined as total bilirubin > 3 × upper limit of the normal range  (ULN ) accompanied by aspartate 
aminotransferase ( AST ) > ULN (assessed at screening); and/or Child -Pugh Class C.  
13. Serum AST and/or alanine aminotransferase ( ALT ) > 3 × ULN (assessed at 
screening).  
14. Severe renal impairment (estimated creatinine clearance ≤ 30 mL/min/1.73  m2) 
assessed at screening.  
15. Ongoing or planned dialysis. 
16. Hemoglobin < 100 g/L assessed at screening . 
17. Known or suspected uncontrolled thyroid disea se (hypo - or hyperthyroidism).  
18. Loss of vision in one or both eyes because of non -arteritic ischemic optic neuropathy 
(NAION).  
19. Treatment with strong inducers of cytochrome P450 3A4 ( CYP3A4 ; 
e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, 
phenytoin, and St. John’ s wort) ≤  28 days prior to Day 1.  
20. Treatment with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)  
and/or strong inhibitors of CYP2C8 (e.g., gemfibrozil) ≤  28 days prior to Day 1.  
[STUDY_ID_REMOVED]
21. Treatment with another investigational drug (planned, or taken ≤ 12 weeks prior to 
Day 1 ). 
22. Hypersensitivity to any of the 3 study treatments or any excipient of their formulations  
(lactose, magnesium stearate, microcrystalline cellulose, hydroxypropyl cellulose, 
povidone, corn starch, sodium starch glycolate type A, polyvinyl alcohol, polysorbate 80, titanium dioxide, talc, xanthan gum, lecithin from soya, croscarmellose sodium, hypromellose, sodium laurylsulfate, triacetin, iron oxide yellow, iron oxide red, iron 
oxide black, d-mannitol, propylene glycol, carnauba wax).  
23. Pregnancy, breastfeeding, or intention to become pregnant during the study.  
24. Concomitant life -threatening disease with a life expectancy < 12 months.  
25. Alcohol abuse.  
26. Any factor or condition likely to affect protocol compliance of the subject , as judged 
by the investigator.  
4.5 Criteria for women of childbearing potential 
4.5.1 Definition of childbearing potential  
A woman is considered to be of childbearing potential unless she meets at least one of the following criteria:  
− Previous bilateral salpingectomy, bilateral salpingo -oophorectomy, or hysterectomy.  
− Premature ovarian failure confirmed by a specialist.  
− XY genotype, Turner syndrome, uterine agenesis. 
− Postmenopausal, defined as 12 consecutive months with no menses without an alternative medical cause (ICH M3 definition).  
4.5.2 Acceptable methods of contraception  
Women of childbearing potential as defined in Section  4.5.1 must use reliable 
contraception from screening up to 1 month following discontinuation of the last study treatment . Reliable contraception must be started at least 11 days p rior to Day 1. The 
methods of contraception used (including non- pharmacological methods) must be recorded 
in the electronic Case Report Form ( eCRF ) at every visit .  
Europe  and other areas outside of Australia and North America  
Use of at least one of the following methods is regarded as reliable contraception:  1. Oral, implantable, transdermal, or injectable hormonal contraceptives or intrauterine devices, or  
2. True abstinence from intercourse with a male partner only when this  is in line with the 
preferred lifestyle of the subject , or  
[STUDY_ID_REMOVED]
3. Permanent female sterilization (tubal occlusion/ligation at least 6 weeks prior to screening), or  
4. Sterilization of the male partner, with documented post -vasectomy confirmation of the 
absence of sperm in the ejaculate.  
Rhythm methods, use of a condom by the male partner alone, use of a female condom or diaphragm alone are not considered acceptable methods of contraception for this study.  Australia  
In females of childbearing potential, pregnancy should be excluded before the start of treatment and prevented thereafter by the use of two reliable methods of contraception. If necessary, patients should discuss with their doctor or gynecologist which methods would be most suitable for them. Giv en the teratogenic nature of macitentan, women should not 
become pregnant for 3 months after discontinuation of the drug. North Amer ica 
For North America, u se of one of the following options is regarded as reliable 
contraception:  
 
4.6 Medical history 
Relevant med ical history as defined in Section  7.1.3 must be recorded in the e CRF.  
[STUDY_ID_REMOVED]
5 TREATMENTS 
5.1 Study treatment  
Study treatments are macitentan, tadalafil, and selex ipag/placebo . Details and references 
are provided in Section 1.2. 5.1.1 Investigational treatment : description and rationale  
The investigational group will receive the following:  
o Macitentan oral tablet, 10 mg once daily  (preferably always in the morning or 
always in the evening; to be recorded in the eCRF ).  
o Tadalafil oral tablet, 20 mg one or two tablets once daily ( preferably always in the 
morning or always in the evening; to be recorded in the eCRF).  
o Selexipag  oral tablet , 200 µg, one to eight tablets twice daily  (in the morning and 
in the evening) . Exceptions from the twice daily dosing regime n are described in 
Section 5.1.3.  
The dose s are in accordance with the IB for macitentan [Macitentan IB ], the product 
labeling for  tadalafil  [Adcirca SmPC , Adcirca USPI ], and the IB for  selexipag  
[Selexipag  IB].  
5.1.2 Comparator treatment : description and rationale 
The comparator group will receive the following: 
o Macitentan oral tablet, 10 mg once daily  (preferably always in the morning or 
always in the evening; to be recorded in the eCRF ).  
o Tadalafil oral tablet, 20 mg one or two tablets once daily ( preferably always in the 
morning or always in the evening; to be recorded in the eCRF).  
o Matching placebo to selexipag  oral tablet , 200 µg, one to eight tablets twice daily  
(in the morning and in the evening) . Exceptions from the twice daily dosing 
regimen are described in Section 5.1.3.  
The doses are in accordance with the IB for macitentan [ Macitentan IB ], the product 
labeling  for tadalafil [ Adcirca SmPC , Adcirca USPI ], and the IB for selexipag 
[Selexipag  IB].  
5.1.3 Study treatment administration  
The 3 study treatments are administered  as follows:  
o Day 1: Start of open -label macitentan 10 mg once daily and open- label tadalafil 
20 mg once daily.  
o Day 8 ±  3: Tadalafil dose increase to 40 mg once daily ( in subject s with mild or 
moderate renal impairment, defined as creatinine clearance > 30 and 
[STUDY_ID_REMOVED]
≤ 80 mL/min/1.73 m2, tadalafil up -titration to 40 mg once daily should be based on 
individual tolerability  [Adcirca SmPC , Adcirca USPI ]).  
o Day 15 ±  3: Start of double-blind selexipag or placebo, see details below. 
Double- blind treatment should be started even in subjects who had to previously 
discontinue one or both of the ot her study treatments.  
The starting dose  of double -blind selexipag or placebo on Day 15 ±  3 is 200 µg twice daily  
(in the morning and in the evening) . The dose is up- titrated  in increments  of 200 µg twice 
daily , usually at weekly intervals [ see Table 2], until either a maximum dose of 1600 µg 
twice daily is reached or adverse pharmacological effects that cannot be tolerated or medically managed are experienced, whichever is first . In the event of adverse effects 
typical of prostanoid therapy, i t is recommend ed not to discontinue double -blind treatment 
because these effects  are usually transient or manageable with symptomatic treatment.  If a 
dose that cannot be  tolerated is reached, the dose should be reduced to the previous dose 
level .  
The goal of the titration is  to identify the individual ly appropriate dose for each subject (the 
maximum tolerated dose [MTD ]) to be used during the maintenance treatment period, i.e. , 
after titration has been completed . The MTD is defined as the first dose used  after the Week 
12 visit. Later dose changes are at the discretion of the investigator , i.e., dose adjustment s 
of selexipag/placebo  (up to the maximum dose of 1600 µg twice daily ) are allowed at any 
time after reaching the MTD . The date and dose at every dose change are recorded on a 
dedicated page in the eCRF.  A once -daily regimen (one to eight tablets once in the morning or in the evening)  is 
recommended in patients with moderate hepatic impairment (Child -Pugh class B) due to 
the increased exposure to selexipag and its active metabolite.  
In case of concomitant administration of a moderate inhibitor of CYP2C8 (e.g., clopidogrel, deferasirox, teriflunomide) , the dosing frequency of selexipag/placebo should 
be reduced to once daily because of drug -drug interactions. A drug -drug interaction study 
showed that clopidogrel had no relevant effect on the exposure to selexipag but increased the exposure to the active  metabolite approximately 2.7- fold at steady -state. The dosing 
frequency should be reverted to twice daily when co- administration of the moderate 
CYP2C8 inhibitor is stopped [ Selexipag IB ]. 
In case of concomitant administration of a moderate inducer of CYP2C8 (e.g., rifampicin ), 
dose adjustment of selexipag/ placebo may be required  because of  drug-drug interactions . 
A drug -drug interaction study showed that  rifampicin did  not lead to a relevant change in 
exposure to selexipag, whereas exposure to the active metabolite decreased by half  
[Selexipag IB ]. 
[STUDY_ID_REMOVED]
Table 2 Double -blind up- titration scheme  up to the Week 12 visit  
Duration (Study Days, all ± 3) Dose regimen1, 2, 3 
Day 15 to Day 21  200 µg twice daily  (1 tablet twice daily ) 
Day 22 to Day 28 400 µg twice daily  (2 tablets twice daily ) 
Day 29  to Day 35 600 µg twice daily  (3 tablets twice daily ) 
Day 36  to Day 42 800 µg twice daily  (4 tablets twice daily ) 
Day 43  to Day 49  1000 µg twice daily  (5 tablets twice daily ) 
Day 50  to Day 56 1200 µg twice daily  (6 tablets twice daily ) 
Day 57  to Day 63 1400 µg twice daily  (7 tablets twice daily ) 
Day 64  to Week 12  visit 1600 µg twice daily  (8 tablets twice daily ) 
1 Or maximum tolerated dose. The indicated doses are target doses if previous dose level was tolerated or if 
tolerability issues were address ed by down- titration.  
2 When titrating up or down , it is recommended to take t he first  new dose in the evening.  
3 Exceptions from the twice daily dosing regimen are described in S ection 5.1.3 . 
 For all 3 study treatments, tablets are to be taken orally, with or without food. Tolerability may be improved when taken with food. The tablets should not be split, crushed or chewed, and are to be swallowed with some water. If a dose has been missed, the subject  must take 
it as soon as possible ( unless the next dose is within the next 6 hours ), and then take the 
next dose at the next scheduled time . 
5.1.4 Treatment assignment  
At Screening, subje cts will be assigned a study -specific subject number by the Interactive 
Response Technology (IRT) system. This number is kept throughout the study and is the main subject identifier. Note: In case of re -screening, the original number will also be used 
the second time.  At the randomization visit, after having confirmed the eligibility of the subject and prior to the start of study treatment, the subject will be randomized. The IRT system will assign a randomization number to the subject  (in addition to the subject number mentioned above) , 
and assign the treatment container number which matches the treatment arm assigned by the randomization list to the randomization number.  The randomization list is generated by an independent Contract Research Organization (CRO), Almac.  
Randomization will be done in a 1:1 ratio. Stratification will be by region (North America  
versus rest of world ) and WHO FC at baseline (I/II versus III/IV).  
[STUDY_ID_REMOVED]
5.1.5 Blinding  
The study will be performed in an open- label fashion for macitentan and tadalafil.  
The study will be performed in a double -blind fashion for selexipag and its matching 
placebo . Selexipag and its matching placebo are i ndistinguishable and all treatment kits 
will be packaged in the same way.  The investigator and study staff, the subjects, the monitors, Actelion staff , and CROs 
involved in the conduct of the study will remain blinded to the study treatment until 
database closure. Actelion staff responsible for clinical trial supply distribution  will need 
to be unblinded to ensure adequate distribution of study treatment. These persons will be clearly identified, their unblinding will be documented in the trial master file and they will not take part in any C linical Trial Team meeting s after stud y set-up has been completed.  
Until the time of unblinding for final data analysis, the randomization list is kept strictly confidential, and accessible only to authorized persons who are not involved in the conduct of the study.  5.1.6 Unblinding  
5.1.6.1 Unblinding for final analyses  
Full randomization information will be made available for data analysis only after database closure (following EOMOP) in accordance with Actelion Standard Operating Procedures 
(SOPs ). The treatment group allocation (selexipag or placebo) will be provided to study 
sites approximately 1 month prior to EOT.  5.1.6.2 Unblinding for interim analyses 
A formal interim analysis is p lanned. In addition, an IDMC will review efficacy, safety and 
tolerability data at regular time intervals. The access to random ization information will in 
any case be limited to the independent Statistical Analysis Center (SAC) which will prepare 
all outputs for the interim analysis and the analyses req uired for the IDMC. The SAC will 
be represented by an independent statistician.  5.1.6.3 Unblinding for suspected unexpected serious adverse reaction s 
When a reported SAE qualifying as a suspected unexpected serious adverse reaction (SUSAR ) for any of the administered study tre atments occurs for a subject participating in 
the study, Actelion Global Drug Safety will request the unblinding of the treatment assignment only if the reported SAE is assessed as related to blinded study medication (selexipag or placebo) and if this event is not listed in Selexipag IB reference safety 
information s ection [ Selexipag IB ] or does  not represent an event that is  PAH disease 
related [see Section  10.2.5] . The randomization code will not be communicated to the site 
staff or to the Actelion study team; unblinded SUSAR information will be anonymized and 
[STUDY_ID_REMOVED]
provided to Actelion Global Drug Safety, regulatory authorities, and IRBs/IECs only. SUSARs will be reported to investigators in a blinded fashion with regard to blinded study medication.  No systematic unblinding of treatment assignment of blinded study medication is requir ed 
if the reported SUSAR qualifies for the open -label study medication(s), macitentan or 
tadalafil.  
5.1.6.4 Emergency procedure for unblinding  
The investigator, study staff , and sponsor staff must remain blinded to the subject ’s study 
treatment assignment. The identity of the study treatment may be revealed only if the subject experiences a medical event, the management of which requires  knowledge of the 
treatment assignment. In this case, the investigator can receive the unblinded randomization code for study tre atment allocation through the IRT. In these situations, the 
decision to unblind resides solely with the investigator. Whenever possible and if it does not interfere with or delay  any decision in the best interest of the subj ect, the investigator 
is requested  to discuss the intended unblinding with Actelion.   
The occurrence of any unblinding during the study must be clearly justified and explained by the investigator. In all cases, Actelion must be informed as soon as possible before or after the unblinding. The circumstances leading to unblinding must be documented in the Investigator Site File 
(ISF)  and e CRF.  
5.1.7 Study treatment supply  
Manufacturing , labeling, packaging , and supply of study treatments will be  conducted 
according to Good Manufacturing Practice, Good Clinical Practice (GCP) , and any local 
or national regulatory requirements. All study treatment supplies will be used only in accordance with this protocol, and not for 
any other purpose.  5.1.7.1 Study tre atment packaging and labeling 
5.1.7.1.1 Study treatment packaging 
Study treatment is provided as tablets  for all 3 study treatments. All 3 study treatments are 
provided in childproof kits.  5.1.7.1.2 Study treatment labeling 
Study treatment is labeled to comply with the applicable laws and regulations of the countries in which the study sites are located.  
[STUDY_ID_REMOVED]
5.1.7.2 Study treatment distribution and storage 
The investigator is responsible for safe and proper handling and storage of the study treatments at the investigational site, and for ensuring that the study treatments are administered only to subjects enrolled in the study and in accordance with the prot ocol. 
Study treatments must be kept in a locked cabinet or room, which can be accessed only by the pharmacist, the investigator, or another duly designated person.  Study t reatment supplies must be stored according to the conditions specified on the 
container label s.  
5.1.7.3 Study treatment dispensing  
The subjects will receive sufficient study treatment to cover the period up to the next scheduled visit. Subjects will be  asked to return all used, partially used, and unused study 
treatment (including the kits ) at each visit. The protocol -mandated study treatment 
dispensing/return procedures may not be altered without prior written approval from 
Actelion.  An accurate record of the date and amount of study treatment dispensed to each 
subject must be available for inspection at any time.   
5.1.7.4 Study treatment return and destruction  
On an ongoing basis and/or on termination of the study, the monitor will  collect used and 
unused treatment  kits, which will be sent to the warehouse, where Actelion or a deputy will 
check treatmen t reconciliation. In certain circumstances, used and unused study treatment 
containers may be destroyed at the site once study treatment accountability is finalized and 
has been checked by Actelion or the deputy, and written permission for destruction has been obtained from Actelion.  5.1.8 Study treatment accountability and compliance with study treatment  
5.1.8.1 Study treatment accountability  
The inventory of study treatment dispensed and returned (i.e., study treatment 
accountability) must be performed by the study staff on the day of the subject visit and before dispensing further study treatment. It is recorded  on the investigational medicinal 
product dispensing and accountability log and checked by the Clin ical Research Associate 
(CRA) during site visits and at th e end of the study. The study treatment accountability log 
will include at least the following information  for each study treatment unit (kit) dispensed 
to the subject, for each of the 3 study treatments: • Dispensed kit number 
• Date dispensed / Number of tab lets dispensed (pre-populated in e CRF ) 
• Date returned  / Number of tablets returned  
[STUDY_ID_REMOVED]
All study treatment supplies, including partially used or empty kits  must be retained at the 
site for review by the CRA.   
If the subject forgets to bring the remaining study treatment to a study visit, he/she must be 
instructe d to not take any tablet s from the remaining study treatment and to bring it at the 
next visit.   
5.1.8.2 Study treatment compliance 
Study treatment compliance is based on study treatment accountability . Study tre atment 
compliance must be calculated at each visit using the formula below , separately for the 
3 study treatments :  
Compliance =  
[(number of tablets dispensed - number of table ts returned) / total number of t ablets that 
should have been taken during the respective period between 2 visits ] × 100 
During the study, compliance is expected to be between 80% and 120%. If out of range value(s) are noticed for any of the 3 study treatments (from study treatment accountability), 
they will be considered as a protocol deviation. The investigator must check with the 
subject the reasons for this non- compliance and discuss actions to be taken to avoid 
recurrence at the next visit.   
Compliance of selexipag wil l not be assessed for the period up to the Week 12 visit.  
5.1.9 Study treatment dose adjustments and interruptions  
Any of the 3 study treatment s may be temporarily interrupted if required due to an AE, a 
tolerability issue, a diagnostic or therapeutic procedure, a laboratory abnormality, or for 
administrative reasons. Interruptions of study treatment s should be kept as short as 
possible. Interruptions must be for less than 4 consecutive weeks; longer interruptions must 
lead to permanent discontinuation of the re spective study treatment(s). Study- specific 
criteria for interruption of study treatment are described in Section  5.1.11.  
Dose adjustments are permitted for tadalafil ( e.g., reduction from 40 to 20 mg once daily) 
and double-blind selexipag or placebo. No dose adjustment is possible for macitentan.  Any interruption of 3 days or more of blinded selexipag/placebo treatment will require new up-titration. Subjects will start with one tablet (200 µg) twice daily. If this dose is well 
tolerated, the dose will be up- titrated by the investigator in 200 µg increments up to the 
subject ’s maximum dose achieved before interruption. The frequency of dose incre ments 
will be based on the medical judgment of the investigator, considering the subject ’s 
tolerability to selexipag/placebo prior to its interruption.  
[STUDY_ID_REMOVED]
If study treatment intake is interrupted or the dose adjusted by the subject for any reason, she/he mus t immediately inform the investigator .  
Study treatment dose adjustments / interruptions must be recorded in the e CRF.   
5.1.10 Premature discontinuation of study treatment  
The decision to prematurely discontinue any of the 3 study treatments may be made by the 
subject, the investigator , or Actelion. The main reason for discontinuation of study 
treatment and whether it is the decision of the subject, the investigator , or Actelion is  
documented in the e CRF.  However, the subject is not obliged to provide a reason. 
A subject has the right to prematurely discontinue any of the 3 study treatment s at any time 
by withdrawal from study treatment only or by withdrawal from any further participation 
in the study (i.e., premature withdrawal from the study , see Section  9.2).  
The investigator should discontinue study treatment s for a given subject if, on balance, 
he/she believes that continued administration would be contrary to the be st interests of the 
subject.   
Any of the 3 s tudy treatment s may be discontinued in response to an AE, lack of efficacy 
(including disease progression, treatment failure, worsening of subject’s condition), a 
protocol deviation (including eligibility failure, non- compliance with study requirements),  
a diagnostic or therapeutic procedure, a laboratory abnormality, or for administrative reasons.   
Study- specific criteria for discontinuation of study  treatment are described in 
Section  5.1.11.  
A subject who prematurely discontinues all study treatment s and withdraws consent to 
participate in any further study a ssessments is considered as withdrawn from the study. 
Subjects who die or are lost to follow -up are also considered as withdrawn from the study. 
Withdrawal from the study and follow -up medical care of subjects withdrawn from the 
study is described in Secti ons 9.2 and 9.4, respectively.   
5.1.11 Study -specific criteria for interruption / premature discontinuation of study 
treatment  
For more details see the prescribing information or other background information for  the 3 
study treatments [ Macitentan IB , Adcirca SmPC , Adcirca USPI , local prescribing 
information for tadalafil,  Selexipag IB ].  
A) Pregnancy 
If a female subject becomes pregnant  after study start (i.e., signing of informed consent) 
and up to 1 month following discontinuation of the last study treatment , a Pregnancy Form 
[STUDY_ID_REMOVED]
must be completed [see Section  10.3].  Therapy with all  study treatments must be 
discontinued and t he investigator should arrange for any PAH- specific therapy as needed  
[ESC Guidelines ]. In the event  of pregnancy with abortion, the investigator should discuss 
the impact on study treatment with Actelion.  
B) Liver aminotransferases abnormalities  
Interruption of study treatment  
Study treatment with macitentan  must be in terrupted in the following case: 
• Aminotransferases (i.e., ALT and/or AST) ≥  3 and < 8 ×  ULN  
 Perform a re -test of aminotransferases (ALT and AST), total and direct bilirubin, and 
alkaline phosphatase within one week. If AST and/or ALT elevation is confirmed, continue to monitor aminotransferases, total and direct bilirubin, and alkaline phosphatase levels weekly until values return to pre -treatment levels or within normal ranges. If the 
aminotransferase values return to p re-treatment levels or within normal ranges, 
reintroduction of macitentan  can be considered.  
Reintroduction of macitentan  after treatment interruption should only be considered if the 
potential benefits outweigh the potential risks and when liver aminotra nsferase values are 
within pre -treatment levels or within normal ranges. The advice of a hepatologist is 
recommended.   
Liver aminotransferase levels must be checked within 3 days after reintroduction, then again after a further 2 weeks and thereafter at mo nthly intervals .  
Permanent discontinuation of study treatment  
Study treatment with macitentan  must be stopped and its reintroduction is not to be 
considered in any of the following cases:  
• Aminotransferases ≥  8 × ULN .  
• Aminotransferases ≥ 3 × ULN and associated clinical symptoms of liver injury, 
e.g., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu like syndrome (arthralgia, myalgia, fever) . However, t he investigator may consider 
reintroduction of macitentan treatment (as described in the paragraph ‘ Interruption of 
study treatment’ above)  if he/she judges the symptom(s) to be unrelated to the elevated 
aminotransferase levels.  
• Aminotransferases ≥  3 × ULN and associated increase in total bilirubin ≥  2 × ULN .  
Aminotransferases, total and direct bilirubin, and alkaline phosphatase levels must be 
monitored weekly after study treatment discontinuation until values return to pre -treatment 
levels or within normal ranges.  
[STUDY_ID_REMOVED]
Other diagnoses (e.g., viral hepatitis, mononucleosis, toxoplasmosis, cytomegalovirus) and/or etiologies (e.g., acetaminophen- related liver toxicity) should be considered and 
ruled out by performing the appropriate tests.  All liver aminotransferases abnormalities leading to study treatment  interruption or 
discontinuation must be recorded as AEs [see Section  10].  
An ILSDRB  provides ongoing assessment and advice regarding serious hepatic events that 
require further evaluation during the study.  
C) Severe hepatic impairment  
If liver impairment is suspected, a clinical assessment of severity (e.g. , Child -Pugh score) 
should be performed. If the investigator becomes aware that a patient has developed moderate hepatic impairment (e.g., Child -Pugh B) at any time during the study, then it is 
the responsibility of the investigator to evaluate the benefit /risk of keeping the patient on 
any or all of the 3 study treatment s.  
If a patient develops severe hepatic impairment (e.g., Child- Pugh  C), the study drugs 
macitentan, tadalafil, and selexipag/placebo must be discontinued.  Assessment of Child -Pugh score is not a mandatory study assessment.  
D) Severe renal impairment  
Study treatment with tadalafil must be discontinued in the event  of severe renal impairment 
(estimated creatinine clearance ≤ 30 mL/min/1.73 m2).  
E) Pulmonary edema due to PVOD 
If a subject develops pulmonary edema due to PVOD consider discontinuation of the 3 study treatments, and consult the background information  [Macitentan IB , 
Adcirca SmPC , Adcirca USPI , local prescribing information for tadalafil,  Selexipag IB ] 
regarding the risk of pulmonary edema.  
F) Vision disorder 
Study treatment with tadalafil must be discontinued in case of loss of vision in one or both eyes because of NAION .  
[STUDY_ID_REMOVED]
G) Hemoglobin abnormalities  
In case of hemoglobin decrease from baseline∗ of > 20 g/L during study treatment with 
macitentan , a re-test must be performed within 10 days ; additional (local) laboratory 
evaluations may include, but are not limited to, any of the following: • Red blood cell cellular indices (mean corpuscular volume, mean corpuscular 
hemoglobin, mean corpuscular hemoglobin concentration), peripheral blood smear, reticulocyte count, iron status (iron level, serum ferritin, total iron binding capacity, transferrin saturation), lactate dehydrogenase, indirect bilirubin. 
Study treatment with macitentan should be temporarily  interrupted if clinically mandated 
based on the investigator ’s judgment, or in any of the following situations  (unless clearly 
unrelated to macitentan, e.g. , hemoglobin decrease due a bleeding event) : 
− A decrease in hemoglobin to <  80 g/L (< 4.9 mmol/L),  
− A decrease in hemoglobin from baseline
* of >  50 g/L, 
− The need for transfusion. 
Reintroduction of study treatment with macitentan may be c onsidered if hemoglobin 
recovers , i.e., if the hemoglobin value returns to above the lower limit of the normal range 
or to a value close to that at baseline, and if the potential benefits of reintroducing 
macitentan outweigh the potential risks.  
H) Start of a  CYP3A4 or CYP2C8 inducer or inhibitor 
Study treatment with macitentan  and tadalafil  must be discontinued if a strong CYP3A 4 
inducer or inhibitor is started during study treatment with macitentan  and/or tadalafil .  
Selexipag/placebo treatment must be discontinued if a strong CYP2C8 inhibitor (e.g., 
gemfibrozil)  is started . 
In case of concomitant administration of a moderate inhibitor of CYP2C8 (e.g., 
clopidogrel, deferasirox, teriflunomide) , the dosing frequency of selexipag/placebo should 
be reduced to once daily because of drug -drug interactions. A drug -drug interaction study 
showed that clopidogrel had no relevant  effect on the exposure to selexipag but increased 
the exposure to the active metabolite approximately 2.7- fold at steady -state. The dosing 
frequency should be reverted to twice daily when co- administration of the moderate 
CYP2C8 inhibitor is stopped [ Selexipag IB ]. 
In case of concomitant administration of a moderate inducer of CYP2C8 (e.g., rifampicin), dose adjustment of selexipag/placebo may be required because of drug -drug interactions . 
∗ Baseline hemoglobin: last value obtained prior to first intake of macitentan study treatment.  
[STUDY_ID_REMOVED]
A drug -drug interaction study showed that  rifampicin did not lead to a relevant change in 
exposure to selexipag, whereas exposure to the active metabolite decreased by half  
[Selexipag IB ].  
I) Start of doxazosin and/or organic nitrates  
Study treatment with tadalafil must be discontinued if doxazosin and/or any organic nitrate 
is started during treatment.  
J) Start of another PAH- specific drug  
Subjects remain in the study irrespective of whether  they are receiving 3, 2, 1, or no study 
treatments, even if another PAH drug is started.  
Study treatment with macitentan must be discontinued if another ERA  is started 
concurrently during macitentan tre atment.  
Study treatment with tadalafil must be discontinued if another PDE -5i or soluble guanylate 
cyclase stimulator  is started concurrently during tadalafil treatment.  
Study treatment with double -blind selexipag/placebo must be discontinued if another 
prostacyclin, prostacyclin analog, or prostacyclin receptor agonist  is started during 
treatment , e.g. , as rescue therapy. Details are described in Section  5.2.5. 
K) Hyperthyroidism or hypothyroidism 
In the event  of clinical suspicion or manifestation of hyper thyroidism or hypothyroidism , 
thyroid function markers including  thyroid stimulating hormone,  free triiodothyronine 
(T3), and free thyroxine (T4)  levels must be monitored by the investigator /delegate  and 
appropriate measures according to local clinical practice should be implemented.  
5.2 Previous and concomitant therapy 
5.2.1 Definitions  
A previous therapy is any treatment for which the end date is prior to the start of study (i.e., 
signing of informed consent).  A study-concomitant therapy is any treatment that is  administered at any time between the 
start of study (i.e., signing of informed consent) and EOS.  A study treatment- concomitant therapy is any treatment that is administered at any time 
between the start of the first study treatment (Day 1) and discontinuation of the last study treatment  (EOT).  
[STUDY_ID_REMOVED]
5.2.2 Reporting of previous/concomitant therapy in the e CRF  
All concomitant therapy (including contraceptives and traditional and alternative 
medicines, i.e., plant -, animal -, or mineral -based medicines , and also cardio -pulmonary 
rehabilitation programs based on exercise) will be recorded in the eCRF. Previous the rapy 
will be recorded in the e CRF if discontinued less than 28 days prior to the start of study  
(i.e., signing of informed consent).  For both previous and concomitant therapy, t he generic name, start/end dates of 
administration (as well as whether it was ongoing at key time points such as EOS), route  of 
administration , dose, and indication will be recorded in the e CRF .  
Single -dose administration of a drug for vasoreactivity testing during RHC should NOT be 
recorded in the eCRF.  
5.2.3 Allowed concomitant therapy  
Single -dose administration of a drug for vasoreactivity testing during RHC.  
Cardio -pulmonary rehabilitation program s based on exercise, started after the Week 26 
visit.  
5.2.4 Forbidden concomitant therapy  
o Any PAH- specific drug ( e.g., ERA , PDE -5i [also if used for erectile dysfunction] , 
soluble guanylate cyclase stimulator, prostacyclin, prostacyclin analog, or prostacyclin receptor agonist)  other than the 3 study treatments  up to EOT , except 
if used as rescue therapy  [see Section  5.2.5] . If another PAH -specific drug is started 
(and the corresponding study treatment is stopped), subjects remain in the study, irrespective of whether they are receiving 3, 2, 1, or no study treatments . See also 
Section 5.1.11, paragraph J.  
o Organic n itrates (other medications with vasodilatory effects must be used with 
caution).  
o Doxazosin. 
o Strong inducers of CYP3A4 (e.g., carbamazepine, rifampin, rifampicin, rifabutin, rifapentin, phenobarbital, phenytoin, and St. John’ s wort) during treatment with 
macitentan and/or tadalafil . 
o Strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, nefazodone, ritonavir, and saquinavir)  during 
treatment with macitentan and/or tadalafil.  
o Strong inhibitors  of CYP2C8 (e .g., gemfibrozil)  during treatment with 
selexipag/placebo . 
o Any investigational drug other than the 3 study treatments. 
o Cardio -pulmonary rehabilitation program s based on exercise  between Screening  
and the Week 26 visit. 
[STUDY_ID_REMOVED]
PAH- specific drugs other than the 3 study treatments are forbidden in order to minimize 
confounding effects on the outcome. Organic n itrates and doxazosin are forbidden in order 
to comply with the prescribing information of tadalafil, strong CYP3A4 inducer s and 
inhibitors are forbidden during treatment with macitentan and/or tadalafil in order to comply with the background information for  macitentan and tadalafil [ Macitentan IB , 
Adcirca SmPC , Adcirca USPI , local prescribing information for tadalafil ]. Strong CYP2C8 
inhibitors are forbidden  during treatment with selexipag/placebo because of drug -drug 
interactions ( as described in  Selexipag IB ).  
Section  5.1.11 describes actions to be taken if a subject takes a forbidden concomitant 
therapy.  
5.2.5 Rescue therapy  
In the event of documented worsening of PAH, it is permitted to use prostacyclin, 
prostacyclin analogs, or prostacyclin receptor agonists as rescue therapy, in parallel to discontinuation of double -blind study treatment. Start of rescue therapy and 
discontinuation of double -blind selexipag or placebo may overlap in order to ensure 
sustained efficacy during the transition. Subjects starting rescue therapy remain in the study until EOS, irrespective of whether they are receiving any of the 3 study treatments .  
6 STUDY ENDPOINTS 
6.1 Efficacy endpoints 
A traditional morbidity/mortality endpoint (as defined in Actelion ’s SERAPHIN and 
GRIPHON trials) does not appear  feasible due to the expected low event rates in the setting 
of the present study (subjects receiving at least two PAH -specif ic drugs). Therefore, the 
trial is designed as a pilot study (with PVR as the primary endpoint) that will explore various disease severity and clinical outcome endpoints.  For the purpose of this study, baseline is defined as the last available assessment from the screening and Day 1 visits.  6.1.1 Primary efficacy endpoint  
The primary endpoint is the ratio of Week 26 to baseline PVR.  RHC is the standard approach for the initial confirmation of the presence of PH , for 
establishing the specific diagnosis  (e.g., PAH), determining the severity of PH , and for 
guiding therapy. PVR as determined by RHC is needed to obtain an objective judgment on the hemodynamic response to treatment and to  improve management. Likewise , PVR is 
associated with disease severity and correlates with mortality. An  increase in PVR leads to 
right ventricular overload, hypertrophy, dilatation, and eventually to right ventricular  
failure and death.  
[STUDY_ID_REMOVED]
6.1.2 Secondary efficacy endpoints  
1. Change from baseline to Week 26 in 6MWD. 
2. Change from baseline to Week 26 in N -terminal pro B -type natriuretic peptide 
(NT-proBNP) . 
3. Absence of worsening from baseline to Week 26 in WHO FC . 
4. Changes from baseline to Week 26 in RHC variables other than PVR (mPAP, cardiac 
index, total pulmonary resistance , mean right atrial pressure ( mRAP ), venous oxygen 
saturation ). 
5. Time from randomization to the first disease progression event up to EOMOP  + 7 days 
(adjudicated by the CEC), defined as any of the following:  
a. Death (all causes; adjudicated for PAH relationship).  
b. Hospitalization for worsening PAH.  
c. Initiation of prostacyclin, a prostacyclin analog, or a prostacyclin receptor agonist for worsening PAH.  
d. Clinical worsening  defined as a post -baseline decrease in 6MWD by > 15% 
from the highest 6MWD obtained at or after baseline , accompanied by WHO 
FC III or IV (both conditions confirmed at two consecutive post -baseline visits 
separated by 1 –21 days).  
6.1.3 Exploratory efficacy endpoints  
1. Changes in NT -proBNP, 6MWD, and WHO FC  from baseline to all regular collection  
timepoints up to EOMOP .  
2. Unsatisfactory clinical response defined as % of subject s meeting at least one of the 
following three condi tions [adapted from McLaughlin 2013] , analyzed at every 
scheduled  visit from Week 26 up to EOMOP : 
a. WHO FC  III or IV.  
b. 6MWD ≤ 440 m AND NT -proBNP ≥ 3 × ULN .  
c. Clinical worsening event as defined under secondary efficacy endpoint 5, at any time up to the respective visit.  
3. Numb er of treatment goals  (score 0  = no or 1 = yes per goal, i.e., total score 0 –5, with 
5 representing  the best treatment outcome ) met at Week 26  [adapted from McLaughlin 
2013]: 
o WHO FC  I or II.   
o Cardiac index > 3 L/min/m
2.  
o mRAP < 8 mmHg.   
o 6MWD > 440 m.  
o NT-proBNP < 3  × ULN .  
4. Number of treatment goals as defined in exploratory efficacy endpoint 3 but using 
> 2.5 L/min/m2 as an alternative cutoff for cardiac index.  
[STUDY_ID_REMOVED]
5. Number of treatment goals as defined in exploratory efficacy endpoint 3 but using 
< 1800 pg/mL as an alternative cutoff for NT- proBNP  [Nickel 2012] .  
6.2 Safety endpoints  
The following safety endpoints will be used: 
o Treatment -emergent AEs.  
o AEs leading to premature discontinuation of any of the 3 study treatments . 
o Treatment -emergent SAEs.  
o Treatment -emergent deaths.  
o Treatment -emergent marked lab oratory abnormalities.  
o Change from baseline in laboratory variables . 
o Change from baseline in vital signs. 
The safety endpoints will be analyzed for the following time periods: 
o From Day 1 until EOMOP .  
o From Day 1 until start of double- blind treatment (selexipag/placebo).  
o From start until discontinuation of macitentan study treatment (or until EOMOP , 
whichever is first) + 30 days safety follow up. 
o From start until discontinuation of tadalafil study treatment (or until EOMOP , 
whichever is first) + 30 days safety follow up. 
o From start until discontinuation of double -blind treatment ( or until  EOMOP , 
whichever is first ) + 30 days safety follow up.  
o From EOMOP  until EOT plus 30 days safety follow-up.  
o The 30 days safety follow-up.  
6.3 Biomarker endpoints  
Based on nonclinical data [Gomez -Arroyo 2015] , it is hypothesized that selexipag may 
have a beneficial effect on circulating biomarkers involved in right ventricular function and structure. Therefore, c hanges in such biomarkers from baseli ne to Week 26 will be 
explored. The list of biomarkers to be m easured after the end of the study will be based on 
the latest scientific evidence regarding right ventricular function and structure at the time of laboratory analysis. No genetic testing of an y kind will be performed  
[see Section  7.3.7.2].  
7 STUDY ASSESSMENTS  
Signed written informed consent is to be obtained prior to any study-mandated procedure.  All study assessments (at scheduled or unscheduled visits) a re performed by  qualified study 
staff member s (medical, nursing, or specialist technical staff ), and are recorded in the e CRF  
(except the central laboratory assessments, see Section 7.3.7).   
[STUDY_ID_REMOVED]
If the principal in vestigator (PI) delegates any study procedure/assessment for a subject to 
an external facility, he/she should inform Actelion to whom these tasks are  delegated. The 
set-up and oversight will be agreed upon with Actelion. The supervision of any external 
facilities remains the responsibility of the P I.  
Calibration certificates for the temperature monitoring device for the study treatment storage area mu st be available prior to screening of the first subject at the site .  
7.1 Screening/baseline assessments 
Table 1 summarizes which assessments are performed at  which visit.  
For subjects who fail screening , only data related to eligibility criteria, demographics and 
baseline characteristics are  collected  in the eCRF .  
7.1.1 Eligibility criteria  
Inclusion and exclusion criteria as listed in Section s 4.3 and 4.4.  
7.1.2 Demographic and baseline characteristics  
• Age, gender, height, weight. 
• Race ( if allowed by local regulations ). 
• PAH etiology  (classification) , date of initial PAH diagnosis. 
7.1.3 Medical history  
The subject ’s relevant medical history up to start of study (i.e., signing of informed 
consent) must be recorded in the eCRF and should include, but is not limited to: • Any chronic medical conditions (e.g., diabetes).  
• Any acute medical conditions in the past 6 months. 
• Any other medically important conditions.  
7.1.4 Previous therapies  
Previous therapies must be recorded in the eCRF  [see Section  5.2.1] .  
7.2 Efficacy assessments 
Table 1 summarizes which assessments are performed at  which visit.  
7.2.1 RHC 
The rationale for using RHC (and PVR as the primary endpoint) is provided in  
Section  6.1.1.  
For the RHC methodology to be used see the Actelion guidelines for RHC [ Appendix 1] .  
[STUDY_ID_REMOVED]
The following variables are determined and entered in the eCRF:  
• PVR  
• Systolic pulmonary artery pressure (sPAP) 
• Diastolic pulmonary artery pressure (dPAP) 
• mPAP  
• PAWP or LVEDP  
• mRAP  
• Cardiac output (CO) 
• Cardiac index  
• Heart rate (HR) during RHC  
• Venous oxygen saturation 
• Systolic systemic artery pressure (sSAP)  
• Diastolic systemic artery pressure (dSAP)  
• Date of the RHC  
7.2.2 6-minute walk test , Borg dyspnea index 
The 6-minute walk test ( 6MWT) [ATS Statement 2002] is a non- encouraged test which 
measures the distance covered over a 6 -minute walk. The ‘Actelion guidelines for 6MWT ’ 
[Appendix 2] must be followed. For subjects who have never performed a 6MWT 
previously, a training test is recommended before the qualifying test for inclusion.  The Borg dyspnea index is evaluated after each 6MWT. It rates dyspnea on a scale from ‘0’ to ‘10’ [ Appendix 3] .  
7.2.3 WHO functional c lass 
WHO FC [ Appendix 4] is a classification which reflects disease severity  based on 
symptoms.  7.2.4 Circulating biomarkers of right ventricular function and structure  
Laboratory  testing of circulating biomarkers of right ventricular function and structure is 
included in Section  7.3.7.2.  
7.2.5 Other efficacy assessments  
Other efficacy assessments are detailed in Section 6.1.  
7.3 Safety assessments 
Table 1 summarizes which assessments are performed at  which visit.  
[STUDY_ID_REMOVED]
7.3.1 (Serious) adv erse events  
The definitions, reporting and follow -up of AEs, SAEs and pregnancies  are described in 
Section  10.  
7.3.2 Contraception  methods  and pregnancy testing  
For women of childbearing potential [ Section  4.5.1], contraception  methods and monthly 
pregnancy testing must be recorded in the eCRF.  
7.3.3 Vital signs  
Systolic and diastolic blood pressure and HR  are measured non- invasively in the same 
position (e.g., supine) throughout the study.  7.3.4 Body w eight  
Body weight is  used for  the calculation of BMI (calculated as body weight in kg divided 
by height in m
2) and of hemodynamic indices.  
7.3.5 Physical examination 
Physical examination (i.e., inspection, percussion, palpation, and auscultation) is 
performed during the study. The observations should be reported according to body system in the e CRF as either normal or abnormal. If abnormal , this should be specified on the 
corresponding e CRF page. Clinically relevant findings (other than those related to PAH) 
that are present at study start (i.e. , signing of informed consent) must be recorded on t he 
Medical History e CRF page. Findings made after study start which meet the definition of 
an AE [Section  10.1.1] must be recorded on the AE page of the eCRF.   
7.3.6 Concomitant therapies  
Concomitant therapies must be recorded in the eCRF [ see Section  5.2].  
7.3.7 Laboratory assessments 
7.3.7.1 Type of laboratory 
A central laboratory (see central laboratory manual for contact details) will be used for all 
protocol- mandated laboratory tests, including re -tests due to laboratory abnormalities and 
laboratory tests performed at unscheduled visits. Central laboratory data will be loaded into the clinical database, i.e., no entry into the eCRF is required for central laboratory data.  Eligibility of subjects at Screening may alternatively be determined using local laboratory 
tests as long as the central laboratory kit is used in par allel. Local laboratory results alone 
may be sufficient in other except ional situations  (e.g., subject is hospitalized in a different 
hospital due to a medical emergency ). Local laboratory data including the normal ranges 
must be entered on  dedicated eCRF  pages . The investigator/delegate will provide Actelion 
with the name, professional degree, and curriculum vitae  of the director of the local 
[STUDY_ID_REMOVED]
laboratory, a copy of the laboratory ’s certification, and the normal ranges for each 
laboratory tes t that is evaluated locally . These laboratory references must be updated 
whenever necessary.  
Under specific circumstances (e.g., if the subject lives far from the site and cannot return 
every month for liver and hemoglobin testing ), laboratory samples may be collected at a 
laboratory close to where the subject lives  (satellite laboratory)  or by a phlebotomy service 
at the subject ’s home, and sent to the central laboratory for analysis. In such a case, the 
satellite laboratory or phlebotomy service must be provided with the central laboratory 
sampling kits. Shipment of the samples will be organized by the satellite laboratory. If this 
process is implemented , the satellite laborato ry must be identified prior to randomization 
of the subject . The supervision of the satellite laboratory remains the responsibility of the 
PI. The supervision of the phlebotomy service is the responsibility of Actelion.  If a central laboratory sample is lost or cannot be analyzed, the investigator /delegate  will 
collect an ad ditional sample as soon as possible to  repeat the analysis, unless a local 
laboratory sample was  collected within the same time window and these test results are 
available.   
Central laboratory reports will be sent to the study site . In the event  of specifi c laboratory 
abnormalities  (pre-defined threshold values) , the central laboratory will alert Actelion and 
the concerned  study site [ Appendix 5].   
All laboratory reports must be signed and dated by the investigator or delegate within 
3 working days of receipt and filed with the source documentation. The 
investigator/delegate must indica te on the laboratory report whether abnormal values are 
considered clinically relevant or not. Clinically relevant laboratory findings that are known at the time of signature of informed consent must be recorded on the medical history page of the e CRF. Any  clinically relevant laboratory abnormalities detected after signature of 
informed consent  must be reported as an AE or SAE as appropriate [see Section  10], and 
must be followed until the value returns to within the normal range or is stable, or until the change is no longer clinically relevant. Further laboratory analyses should be performed as clinically indicated and according to the judgment of the investigator.  Details about the collection, sampling, storage, shipment procedures, and reporting of results and abnormal findings can be found in the laboratory manual.  7.3.7.2 Laboratory tests 
In Table 1 and S ection  8, the following are summarized as ‘ general ’ laboratory tests: 
Hematology, clinical chemistry  including liver and hemoglobin tests, coagulation tests, and 
NT-proBNP.  
[STUDY_ID_REMOVED]
Hematology  
Rules for additional investigations and study treatment interruption in case of hemoglobin abnormalities are provided in Section  5.1.11.  
• Hemoglobin 
• Hematocrit  
• Erythrocyte c ount (reticulocyte count)  
• Leukocyte count with differential counts 
• Platelet count  
Clinical chemistry  
Rules for study treatment interruption in case of liver enzymes abnormalities or severe renal impairment are provided in Section  5.1.11.  
The Cockcroft -Gault formula is used for estimation of the creatinine clearance: Estimated 
creatine clearance rate = (140 – age) × (weight in kg) × (1.23 for men and 1.04 for women), 
divided by serum creatinine in μmol/L.  
• Aminotransferases (AST/ALT), alkaline phosphatase, total and direct bilirubin, lactate dehydrogenase  
• Creatinine, urea 
• Uric acid  (serum urate)  
• Glucose 
• Sodium, potassium, chloride, calcium 
• Protein, albumin 
Coagulation tests  
• International Normalized Ratio  
• Prothrombin time  
• Activated partial thromboplastin time  
Pregnancy test  
Monthly (± 1 week)  pregnancy tests are done for women of childbearing potential [ as 
defined in Section  4.5.1]. For details, see Table 1, including footnotes. 
Pregnancy reporting requirements are described in Section  10.3. Also see Section  5.1.11.  
Biomarkers of myocardial stress  and of right ventricular function and structure 
• NT-proBNP  
[STUDY_ID_REMOVED]
• Circulating biomarkers involved in right ventricular function and structure (blood samples will be stored at the central laboratory or a specialized laboratory for up to two years after the last subject ’s last visit and destroyed after that date. The list of 
biomarkers to be measured after the end of the study will be based on the latest scientific evidence regarding right ventricular function and structure at the time of laboratory analysis. No genetic t esting of any kind will be performed) .  
8 SCHEDULE OF VISITS 
For a tabulated summary of all visits and assessments described here  see Table 1. For a 
description of the assessment methods see Section 7.  For this clinical trial, a month is d efined as 30 days. 
All assessments except the central laboratory results must be recorded in the eCRF.  
Monthly (± 1 week)  central laboratory testing of liver aminotransferases , total and direct 
bilirubin, and hemoglobin is mandatory throughout the study . For monthly testing , blood 
drawing is performed either at the study site, at a satellite lab oratory close to where the 
subject lives, or by a phlebotomy service at the subject’s home.  In women of childbearing potential [Section 4.5.1 ], serum pregnancy tests are performed 
at Screening, Week 12, Week 26, monthly (± 1 week) throughout the study , at EOMOP, 
EOT, and if pregnancy is suspected at any time during the study. Urine pregnancy tests are 
performed at the Day 1 visit and if  a monthly serum test is missed. At EOS either serum or 
urine pregnancy tests are performed . To ensure compliance, at each visit, the study 
personnel must remind women of childbearing potential to perform monthly pregnancy tests and to use reliable contraception as defined for this study  [Section 4.5.2] ; the 
reminders must be documented in the hospital chart.  
8.1 Screening period  
It is the responsibility of the investigator to obtain written informed consent ( Informed 
Consent F orm [ICF]) from each patient participating in the study after adequate 
explanation of the objectives, methods, and potential benefits and hazards of the study. The ICF must be signed and dated by both parties prior to any study assessment or procedure. However, RHC data o btained at the study site within 28 days prior to Day 1 but before the 
study (i.e., before signed informed consent) are acceptable.  Assessments of the screening period must be performed between Day − 28 and the Day 1 
(enrollment/randomization) visit. R eliable contraception [defined in Section 4.5.2] must be 
started at least 11 days prior to Day 1.  It is permitted to re -screen subjects once, if the reason for non- eligibility was transient (e.g., 
abnormal laboratory test, insufficient wash- out period of a forbidden medication). All 
[STUDY_ID_REMOVED]
screening assessments should then be repeated at the time of re -screen ing (including 
signature of the ICF if the first ICF was signed more than 28 days prior to Day  1 [i.e., 
randomization]). The screening period includes recording of the following [see Table 1]:  
• Check of eligibility (inclusion and exclusion criteria) 
• Demographics 
• Medical history  
• RHC  
• Physical examination  
• Vital signs (BP, HR)  
• WHO FC  
• 6MWD, Borg dyspnea index 
• Central laboratory tests (general, serum pregnancy test, and bioma rkers); e ligibility 
of subjects at Screening may alternatively be determined using local laboratory tests as long as the central laboratory kit is used in parallel 
• Contraceptive methods used 
• Previous therapies 
• AEs, SAEs  
8.2 Treatment period  
For monthly central  laboratory testing requirements during the treatment phase see footnote 
9 of the Visit and assessment schedule [ Table 1].  
8.2.1 Day 1 (randomization) visit 
The Day 1 (ran domization) visit includes recording of the following [see  Table 1]:  
• Vital signs (BP, HR) *  
• WHO FC  * 
• 6MWD, Borg dyspnea index * 
• Central laboratory tests (general) *  
• Urine pregnancy test  
• Contraceptive methods used 
• Concomitant therapies 
• AEs, SAEs  
* Only required if the respective assessment from the screening period was obtained more than 7 days prior to the Day 1  visit.  
[STUDY_ID_REMOVED]
At the end of this visit, subjects are randomized  to one of the two treatment groups. 
Macitentan and tadalafil study treatments are dispensed to the subjects . Treatment is 
initiated as described in Section 5.1.  8.2.2 Day 8 visit  
The Day 8 (± 3 days) visit may be performed as a phone call and includes recording of the following [see Table 1]:  
• AEs, SAEs  
At the end of this visit, the  dose of tadalafil is increased as described in Section 5.1.  
8.2.3 Day 15 visit  
The Day 15 (± 3 days) visit includes recording of the following [see Table 1 ]: 
• Physical examination  
• Vital signs (BP, HR)  
• Contraceptive methods used 
• Concomitant therapies 
• AEs, SAEs  
At the end of this visit, double -blind selexipag/placebo is dispensed to the subjects . The 
subjects initiate treatment and up- titration (on top of ongoing study treatment with 
macitentan and tadalafil) as described in Section 5.1.  8.2.4 Weekly phone calls during up- titration  
Weekly phone calls are performed during the up- titration phase of double -blind study 
treatment. They include instructing the subjects regarding the dose of double -blind study 
treatment and recording of the following [see Table 1]:  
• AEs, SAEs  
8.2.5 Week 12 visit  
The Week 12 (± 1 week) visit includes recording of the follow ing [see Table 1]:  
• Physical examination  
• Vital signs (BP, HR)  
• WHO FC  
• 6MWD, Borg dyspnea index 
• Central laboratory tests (general, serum pregnancy test)  
• Contraceptive methods used 
• Concomitant therapies 
[STUDY_ID_REMOVED]
• AEs, SAEs  
At this visit, study treatments are dispensed and returned as described in Section 5.1.  8.2.6 Week 26  visit  
The Week 26 (± 1 week) visit includes recording of the following [see Table 1]:  
• RHC  
• Physical examination  
• Vital signs (BP, HR)  
• WHO FC  
• 6MWD, Borg dyspnea index 
• Central laboratory tests (general, serum pregnancy test, and biomarkers) 
• Contraceptive methods used 
• Concomitant therapies 
• AEs, SAEs  
At this visit, study treatments are dispensed and returned as described in Section 5.1.  8.2.7 Month 12, 18, 24, 30, etc. visits  
The Month 12, 18, 24, 30, etc. (± 2 weeks) visits include recording of the following [see 
Table 1]:  
• Physical examination  
• Vital signs (BP, HR)  
• WHO FC  
• 6MWD, Borg dyspnea index 
• Central laboratory tests (general, serum pregnancy test)  
• Contraceptive methods used 
• Concomitant therapies 
• AEs, SAEs  
At these  visits, study treatments are dispensed and returned as described in Section 5.1.  
8.2.8 EOMOP  visit  
The EOMOP  visit [see Section 3.1] includes recording of the following [see Table 1]:  
• Physical examination  
• Vital signs (BP, HR)  
• WHO FC  
• 6MWD, Borg dyspnea index  
• Central laboratory tests (general,  serum pregnancy test)  
[STUDY_ID_REMOVED]
• Contraceptive methods used 
• Concomitant therapies 
• AEs, SAEs  
At this  visit, study treatments are dispensed and returned as described in Section 5.1.  
8.2.9 EOT visit  
The EOT visit [Section 3.1 ] includes recording of the following [see Table 1]: 
• Physical examination  
• Vital signs (BP, HR)  
• WHO FC  
• 6MWD, Borg dyspnea index 
• Central laboratory tests (general, serum pregnancy test)  
• Contraceptive methods used 
• Concomitant therapies 
• AEs, SAEs  
At this visit, all study treatments are returned by the subjects, as described in Section 5.1.  8.2.10 Unscheduled visits  
Unscheduled visits may be performed at any time during the study. Depending on the reason for the unscheduled visit (e.g., AE), appropriate assessments will be performed 
based on the judgment of the investigator and the results will be recorded in the eCRF. After an unscheduled visit, the regular scheduled study visits must continue according to the visit and assessment schedule in Table 1.  If any post -baseline decrease in 6MWD by > 15% from the highest 6MWD obtained at or 
after screening is observed, accompanied by WHO FC III or IV, then both the 6MWD and WHO FC must be reassessed at an unscheduled visit after 1 –21 days.  
8.3 Safety follow-up  
All subjects undergo a 30 days safety follow-up prior to EOS.  
8.3.1 EOS visit  
The EOS visit may be performed as a phone call. It is performed at the end of the safety follow-up, i.e., 30–35 days after EOT.  The EOS visit includes recording of the following [see Table 1]:  
• Pregnancy test (serum or urine)  
• Contraceptive methods used 
[STUDY_ID_REMOVED]
• AEs, SAEs  
9 STUDY COMPLETION AND POST-STUDY TREATMENT/MEDICAL CARE 
9.1 Study completion  
Sites will be informed once the planned total subject enrollment is met. Subjects in 
screening (i.e., signed informed consent available but not yet randomized) at that point in time will be allowed to be randomized if they are eligible. No ad ditional subje cts may  be 
screened. All subjects still in the study will be invited for their EOMOP  visit 26 weeks 
after enrollment of the last subject, and for their EOT visit approximately 4 months after EOMOP .  
The end of the study as a whole is the date of the last s ubject ’s EOS  visit.  
9.2 Premature withdrawal of subjects from study 
Subjects may voluntarily withdraw from the study for any reason at any time. Subjects are considered withdrawn if they state an intention to withdraw further participation in all components of the study  (i.e., withdrawal of consent) , die, or are lost to follow -up. If a 
subject withdraws consent, no further data will be collected in the eCRF  from the date of 
withdrawal onward.  The investigator may withdraw a subject from the study (without regard to the subject ’s 
consent) if, on balance, he /she believes that continued participation in the study would be 
contrary to the best interests of the subject. Withdrawal from the study may also result from a decision by Actelion for any reason, including premature termination or suspension of the study [see Section  9.3].   
Subjects are considered as lost to follow -up if all reasonable attempts by the 
investigator /delegate to communicate with the subject fail. T he site must take preventive 
measures to avoid a subject being lost to follow -up (e.g., document different attempts  of 
contact such as via telephone, home address, email address, or a person to be contacted in case the subject cannot be reached). The follo wing methods must be used: at least three 
telephone calls must be placed to the last available telephone number and one registered letter must be sent by post to the last available home address. Additional methods may be acceptable if they are compliant wi th local rules/regulations (e.g., site staff visit to the 
subject ’s home), respecting the subject ’s right to privacy. If the subject is still unreachable 
after all contact attempts listed above, he/she will be considered to be lost to follow -up. 
This is documented in the eCRF.  
[STUDY_ID_REMOVED]
If premature withdrawal from the study occurs for any reason, the reason along with who 
made the decision (subject, investigator , or Actelion) is  recorded in the e CRF.  However, 
the subject is not obliged to provide a reason. If a sub ject is  withdrawn from the study  because of withdrawal of consent , the investigator 
should make efforts to schedule a last appointment /phone call  to assess the safety and well -
being of the subject, collect unused study treatment and discuss follow -up medical care. 
Data obtained during this last appointment /phone call  will be recorded in the subjects ’ 
medical records but it  will not be reported in the e CRF  or SAE Form, unless the subject 
agrees with such reporting . The investigator  must provide follow -up medical care for all 
subjects who are prematurely withdrawn from the study, or must refer them for appropriate ongoing care, as described in Section  9.4.  
9.3 Premature termination or suspension of the study 
Actelion reserves the right to terminate the study at any time globally (e.g. , based on the 
outcome of the interim analysis) or locally. Investigators can terminate the partici pation of 
their site in the study at any time.   
If a study is prematurely suspended or terminated, Actelion will promptly inform the investigators, the IRBs/IECs , and regulatory  authorities, as appropriate, and provide the 
reasons for the suspension or termination.   
If the study is suspended or prematurely terminated for any reason, the investigator in agreement with Actelion must promptly inform all enrolled subjects, and ensure their appropriate treatment and follow-up, as described in Section  9.2. Actelion may inform the 
investigator of additional procedures to be followed in order to ensure that adequate consideration is given to the protection of the subjects’ interests.   
In addition, if the investigator suspends or terminates a study without prior agreement from Actelion, the investigator must promptly inform Actelion and the IRB/IEC, and provide both with a detailed written explanation of the termination or suspension.  If the IRB/IEC suspends or terminates its approval/favorable opinion of a study, the investigator must promptly notify Actelion and provide a detailed written explanation of the termination or suspension.  Any suspension or pre mature termination of the study must be discussed with the IDMC 
and SC.  
9.4 Medical care of subjects after study completion/withdrawal from study 
At the subjects ’ EOT , the investigator/delegate will expla in to subjects what standard 
treatment /medical care is necessary and available according to local regulations. Such care 
may include  commercial PAH -specific drugs.  
[STUDY_ID_REMOVED]
10 SAFETY DEFINITIONS AND REPORTING REQUIREMENTS 
10.1 Adverse events  
10.1.1 Definitions of adverse events  
An AE is any adverse change, i.e., any unfavorable and unintended sign, including an abnormal laboratory finding, symptom , or disease that occurs in a subject during the course 
of the study, whether or not considered by the investigator as related to study treatment. A treatment -emergent AE is any AE temporally associated with the use of study treatment 
(from study treatment initiation until 30 days after last study treatment discontinuation) 
whether or not considered by the investigator as related to study treatment.  AEs include: • Exacerbation of a pre- existing disease.  
• Increase in frequency or intensity of a pre- existing episodic disease or medical 
condition. 
• Disease or medical condition detected or diagnosed during the course of the study even though it may have been present prior to the start of the study. 
• Continuous persistent disease or symptoms present at study start that worsen following the start of the study  (i.e., signing of informed consent). 
• Abnormal assessments, e.g., change on physical examination, ECG findings, if they represent a clinically significant finding that was not present at study start or worsened during the course of the study. 
• Laboratory test abnormalities if they represent a clinically significant finding, symptomatic or not, which was not present at study start or worsened during the course of the study or led to dose reduction, interruption or permanent discontinuation of study treatment.  
Overdose, misuse , and abuse of the study treatment should be reported as an AE and, in 
addition, study treatment errors must be documented in the study treatment log of the  
eCRF . 
10.1.2 Intensity of adverse events  
The intensity of clinical AEs is graded on a three -point scale – mild, moderate, severe – 
and is reported on specific AE pages of the eCRF . 
If the intensity of an AE worsens during study treatment administration, only the worst intensity should be reported on the AE page. If the AE lessens in intensity, no change in the severity is required.  
[STUDY_ID_REMOVED]
If the intensity of an AE with an onset date between informed consent signature and start of study treatment and which is ongoing at the start of treatment worsens after the start of 
study treatment,  a new AE page must be completed. The onset date of this new AE 
corresponds to the date of worsening in intensity. The thr ee categories of intensity are defined as follows:  
 Mild  
The event may be noticeable to the subject. It does not influence daily activities, and usually does not require intervention. 
 Moderate  
The event may make the subject uncomfortable. Performance of daily activities may be influenced, and intervention may be needed. 
 Severe  
The event may cause noticeable discomfort, and usually interferes with daily activities. The subject may not be able to continue in the study, and treatment or intervention is usually needed. A mild, moderate, or severe AE may or may not be serious [ see Section  10.3.1] . These 
terms are used to describe the intensity of a specific event. Medical judgment should be used on a case- by-case basis.  
Seriousness, rather than severity assessment, determines the reg ulatory reporting 
obligations. 10.1.3 Relationship to study treatment  
Each AE must be assessed by the investigator as to whether or not there is a reasonable 
possibility of causal relationship to the study treatment s, and reported as either related or 
unrelated  to macitentan, tadalafil, or blinded study treatment (selexipag/placebo) . The 
determination of the likelihood that the study treatments caused the AE will be provided 
by an investigator who is a qualified physician.   
10.1.4 Adverse events associated to study desig n or protocol- mandated procedures  
An AE is defined as related to study design or protocol -mandated procedures if it appears 
to have a reasonable possibility of a causal relationship to either the study design or to protocol-mandated procedures.  10.1.5 Reporting of adverse events  
All AEs occurr ing after study start (i.e., signing of informed consent) and up to EOS must 
be recorded on specific AE pages of the e CRF.  
[STUDY_ID_REMOVED]
10.1.6 Follow- up of adverse events  
AEs still ongoing more than 30 days after study treatment discontinuation must be followed 
up until they are no longer considered clinically relevant. 
10.2 Serious adverse events 
10.2.1 Definitions of serious adverse events  
10.2.1.1 Serious adverse events  
An SAE is defined by the ICH guidelines as any AE fulfilling at least one of the following criteria:  
• Fatal . 
• Life-threatening: refers to an event in which the subject was at risk of death at the time 
of the event. It does not refer to an event that hypothetically might have caused death had it been more severe.  
• Requiring inpatient hospitalization, or prolongation of existing hospitalization. 
• Resulting in persistent or significant disability or incapacity.  
• Congenital anomaly or birth defect. 
• Medically significant: refers to important medical events that may not immediately result in death, be life -threatening, or require hospitalization but may be considered to 
be SAEs when, based upon appropriate medical judgment, they may jeopardize the subject, and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions above. 
The following reasons for hospitalization are exempted from being reported: • Hospitalization for cosmetic elective surgery, or social and/or convenience reasons. 
• Hospitalization for pre -planned (i.e., planned prior to signing informed consent ) 
surgery or standard monitoring of a pre -existing disease or medical condition that did 
not worsen, e.g., hospitalization for coronary angiography in a subject with stable angina pectoris.  
However, complications that occur during hospitalization are AEs or SAEs (for example if a complication prolongs hospitalization). 10.2.2 Reporting of serious adverse events  
All SAEs occurring after study start (i.e., signing of informed consent) up to EOS must be reported on AE pages in the  eCRF  and on an SAE form , regardless of the 
[STUDY_ID_REMOVED]
investigator -attributed causal relationship with study treatment or study -mandated 
procedures. 10.2.3 Follow- up of serious adverse events  
SAEs still ongoing at the E OS visit must be followed up until resolution or stabilization, 
or until the event outcome is provided, e.g., death. 10.2.4 After the [30 -day] follow- up period 
New SAEs occurring after the 30-days follow- up period must be  reported to the Actelion 
drug safety department within 24 hours of the investigator ’s knowledge of the event, only  
if considered by the investigator to be causally related to previous exposure to any of the 3 
study treatments.  10.2.5 Reporting procedures  
All SAEs must be reported by the investigator to the Actelion drug safety department 
within 24 hours of the investigator’s first knowled ge of the event.  
All SAEs must be recorded on an SAE form, irrespective of the study treatment received by the subject, and whether or not this event is considered by the investigator to be related to any of the study treatments (macitentan, tadalafil, or selexipag/placebo) .  
The SAE forms must be faxed to the Actelion drug safety department (contact details are provided on the SAE form). The investigator must complete the SAE form in English, and 
must assess the causal relationship of the event to study tr eatment.  
Follow- up information about a previously reported SAE must also be reported within 
24 hours of receiving it. The Ac telion drug safety department may contact the investigator 
to obtain further information. If the subject is hospitalized in a hospit al other than the study site, it is the investigator ’s 
responsibility to contact this hospital to obtain all SAE relevant information and documentation. The reference safety document to assess expectedness of a suspect serious adverse reaction and reported by the sponsor to regulatory authorities, IRBs /IECs,  and investigators are the 
background information for the 3 study treatments  [reference safety information section of 
Macitentan IB , Adcirca USPI , reference safety information section of Selexipag IB ].  
The following events that are anticipated  to oc cur in subjects  with PAH will be considered 
as ‘disease- related ’ and will not be subject to unblinding (as applicable) and regulatory 
reporting: signs and symptoms of PAH worsening/exacerbation/progression, abdominal pain, anorexia, chest pain, cyanosis, diaphoresis, dizziness, pre -syncope, syncope,  dyspnea, 
orthopnea, fatigue, hemoptysis, heart failure, hypoxia, palpitations, collapse, systemic 
[STUDY_ID_REMOVED]
arterial  hypotension, and tachycardia. Like all other SAEs, these SAEs must  be reported 
on an SAE form by the investigator to the Actelion drug safety department within 24 hours of the investigator ’s first knowledge of the event , and be reported on the AE page of the 
eCRF .  
10.3 Pregnancy 
If a female subject  becomes pregnant, the instructions in Section 5.1.11 must be followed. 
The investigator must counsel the subject and discuss the risks of continuing with the pregnancy and the possible effects on the fetus.  10.3.1 Reporting of pregnancy  
Irrespective of the treatment received by the subject, any pregnancy occurring  after  study 
start (i.e., signing of informed consent) and  up to 1 month following discontinuation of the 
last of the 3 study treatment s must be reported within 24 hours of the investigator ’s 
knowledge of the event.  Pregnancies must be reported on the Actelion Pregnancy form, which is faxed to the 
Actelion drug safety department (see contact details provided on the Actelion Pregnancy form), and on the AE page in the e CRF.   
10.3.2 Follow- up of pregnancy  
Any pregnancy must be followed to its conclusion and its outcome must be reported to the Actelion  drug safety department.  
Any AE associated with the pregnancy occurring during the follow -up period after study 
treatment  discontinuation must be reported on separate AE pages in the  eCRF . Any SAE 
occurring during the pregnancy must be reported on an SAE form as described in Secti on 10.3.1. 
10.4 Study safety monitoring 
Clinical study safety information (AEs,  SAEs, laboratory values, vital signs, and 
project -specific lab oratorie s/examinations as required) is monitored and reviewed on a 
continuous basis by the Actelion Clinical Team (in charge of ensuring subjects ’ safety as 
well as data quality) by periodically monitoring clinical studies activities from protocol conception to database closure. In addition, an IDMC is monitoring safety data [ see Section  
3.3]. 
11 STATISTICAL METHODS 
All statistical analyses will be conducted by Actelion or by designated C RO supervised by 
Actelion.  
[STUDY_ID_REMOVED]
A Statistical Analysis Plan (SAP) will provide full details of the analyses, data displays, and algorithms to be used for data derivations. 
11.1 Analysis sets 
11.1.1 Screened Analysis Set  
This analysis set includes all subjects who were screened. 11.1.2 Full Analysis Set  
The Full Analysis Set (FAS) includes all randomized subjects. Subjects are e valuated 
according to the study treatment they have been assigned to (which may be different from the study treatment they have received).  
11.1.3 Modified Full Analys is Set  
The Modified Full Analysis Set (Modified FAS) includes all subjects from the FAS who received at least one dose of each of the 3  study treatments (macitentan, tadalafil, and 
double- blind selexipag or placebo). Subjects are evaluated according to the study treatment 
they have been assigned to (which may be different from the study treatment they have received).  
11.1.4 Per-protocol Set  
The Per -protocol S et (PPS) includes all subjects from the FAS who received at least one 
dose of double -blind study treatment  and who have no major protocol deviation. Major 
protocol deviations will be described in the SAP. Subjects are evaluated according to the study treatment they have been assigned to (which may be different from the study 
treatment they have received) . 
11.1.5 Safety Set  
The Safety Set includes all subjects who received at least one dose of any of the 3 study 
treatment s.  
11.1.6 Usage of the analysis sets 
The primary efficacy analysis will be performed on the FAS based on treatment as randomized. Secondary and exploratory efficacy analyses will also be performed on the FAS. The Modified FAS and PPS will be used for sensitivity analyses. 
Safety analyses will be performed on the Safety Set based on treatment as received . 
Subject listings will be based on the Safety Set, unless otherwise specified. Subject disposition will be described for the Screened Analysis Set. 
[STUDY_ID_REMOVED]
11.2 Variables 
11.2.1 Primary efficacy variable 
The primary efficacy variable is the ratio of Week 26 to baseline PVR. In the analyses this variable will be log -transforme d, as log-transformed ratios follow a normal distribution 
more closely. In addition, the mean change from baseline on log  scale can be transformed 
into a geometric mean ratio (GMR) of Week 26 to baseline PVR. A GMR < 1 corresponds 
to a reduction in PVR fro m baseline,  which reflects a positive treatment effect.  
Baseline is defined as the last measurement obtained before or on Day 1 (before 
randomization). 11.2.2 Secondary efficacy variables  
See Section 6.1.2.  11.2.3 Other efficacy variables  
See Section 6.1.3.  11.2.4 Safety variables 
See Section 6.2.  
11.3 Description of statistical analyses 
11.3.1 Overall testing strategy  
The analysis of the primary endpoint, i.e., PVR, will be tested according to the sequential 
group design of this trial. The first look, i.e., the futility interim analysis  (non-binding) , 
will be performed at information time  0.33 (i.e., when 33% of the planned enrolled subjects 
in each arm have completed their Week 26 visit) and the final one at the end of the study 
(i.e., when all subjects have com pleted their Week 26 visit ). The overall type I error will 
be preserved at a 5% level . 
To control for multiplicity across the primary and selected secondary efficacy endpoints, 
statistical analyses for secondary endpoints will be performed in the following sequence: 
change from baseline to Week 26 in 6MWD,  change from baseline to Week 26 in 
NT-proBNP , time from randomization to first disease progression event , and a bsence of 
worsening from baseline to Week 26 in WHO FC. The changes from baseline to Week 26 in other RHC variables will be excluded from this hierarchical testing strategy as they 
include too many variables . 
Secondary efficacy variables will be analyzed for the FAS at α = 0.05 (two- sided) using 
95% CIs. 
[STUDY_ID_REMOVED]
11.3.2 Anal ysis of the primary efficacy variable 
11.3.2.1 Hypotheses and statistical model 
The null hypothesis (H 0) is that the GMR of Week 26 to baseline PVR is equal in the dual 
and triple therapy groups. The alternative hypothesis  (H1) is that these GMRs are different, 
with a difference of –0.223 expressed on a log scale.  
If the GMR of Week 26 to baseline PVR in the triple therapy group is statistically significantly lower than in the dual therapy group, then triple therapy is considered superior to dual therapy. 11.3.2.2 Handling of missing data 
For subjects with a post -baseline PVR measurement obtained before Week 26, the (last) 
post- baseline PVR measurement will be carried forward. For subjects without a 
post- baseline PVR measurement, the baseline PVR will be carried forward (i.e., the ratio 
of Week 26 to baseline set to one). Subjects with missing baseline PVR measurement will be excluded from analysis.  
Since subjects are treated with two or three PAH medications, their PVR is expected to decrease. Subjects that do not complete 26 weeks of treatment will generally have less decrease in PVR as compared to subjects that complete 26 weeks of treatment. On a subject level, the last observation carried forward approach is expected to be conservative. 11.3.2.3 Main analysis 
Following the intent- to-treat principle, the primary analysis will be conducted on the FAS. 
The s ame method will be considered for the primary efficacy endpoint at time of interim 
analysis and at final analysis.  The only difference wil l be the significance level as indi cated 
further below.  The ratio of Week 26 to baseline PVR will be log -transformed (base e) and analyzed using 
an analysis of covariance (ANCOVA) with factors for treatment group, region (as stratified 
at randomization), baseline WHO FC (as stratified) and  a continuous covariate for baseline 
log PVR. The treatment group difference (triple minus dual) and its corresponding CI will be estimated based on the model.  For each treatment group, the GMR of Week 26 to baseline PVR will be obtained by exponentiating the least squares means from the model. The triple versus dual treatment 
group ratio of GMRs and its corresponding CI will be obtained by exponentiating the 
treatment group difference and its  corresponding CI from the model.  
[STUDY_ID_REMOVED]
The null hypothesis will be r ejected if the corresponding CI around the ratio of GMRs 
excludes 1. Triple therapy will be considered superior to dual therapy if the corresponding 
CI is entirely below  1. 
11.3.2.4 Supportive/sensitivity analyses  
Supportive analyses will be performed for the Modif ied FAS  as well as for the PPS.  
Additional sensitivity analyses will be described in the SAP.  
11.3.2.5 Subgroup analyses 
Subgroup analyses will be performed by region and WHO FC  at baseline (I/II versus  
III/IV). Additional subgroups analyses will be described in the SAP.  
11.3.3 Analysis of the secondary efficacy variables 
To control for multiplicity across the primary and selected secondary efficacy endpoints, 
statistical analyses will be  performed in the following sequence: change from baseline to 
Week 26 in 6MWD, change from baseline to Week 26 in NT -proBNP , time from 
randomization to first disease progression event , and absence of worsening from baseline 
to Week 26 in WHO FC. The changes from baseline to Week 26 in other RHC variables 
will be  excluded from this hierarchical testing strategy as they include too many variables . 
Secondary efficacy variables will be analyzed for the FAS at α = 0.05 (two- sided) using 
95% CIs. Change from baseline to Week 26 in NT -proBNP (log -transformed) will be analyzed using 
an ANCOVA with  factors for treatment group, region, baseline WHO FC, and a covariate 
for baseline NT -proBNP (log -transformed).  
Change from baseline to Week 26 in 6MWD will be analyzed using an ANCOVA with the same factors and a continuous covariate for baseline 6MWD.  
Absence of worsening from baseline to Week 26 in WHO FC  will be analyzed using a 
logistic regression model with factors for treatment group, region , and baseline WHO FC. 
Subjects in WHO FC IV at baseline will be excluded from the latter analysis.  A sensitivi ty 
analysis will be performed including subjects in WHO FC IV at baseline (for whom worsening will be defined as death or hospitalization due to PAH).  Changes from baseline to Week 26 in RHC variables other than PVR will be analyzed using an ANCOVA with factors for treatment group, region, baseline WHO FC , and a  
continuous covariate for the baseline value of the variable. Time from randomization to first disease progression  event (censored at EOMOP  plus 
7 days) will be described by Kaplan -Meier plots and analyzed by the logrank test and a 
Cox model with factors for treatment group, region and baseline WHO FC. These analyses 
[STUDY_ID_REMOVED]
will also be performed in the subset of subjects from the FAS who received at least one dose of double-blind study treatment . In that case the variable is defined as time from first 
double- blind study treatment  intake to first disease progression  event (censored at end of 
double-blind study treatment plus 7 days, or EOMOP plus 7 days, whichever is first ). 
The components of the first occurrence of disease progression events will be tabulated by 
treatment group. If for a given subject two components occur on the same day then the 
worst will be tabulated (according to the hierarchy: death, hospitalization, initiation of 
therapy for worsening  PAH, and clinical worsening) . 
Analysis of efficacy variables between EOMOP and EOT (i.e., after the main observation 
period) will be described in the SAP.  11.3.4 Analysis of the other efficacy variables 
Changes from baseline to all regular collection time points in NT -proBNP 
(log-transformed) will be analyzed using a mixed model for repeated measurements with 
factors for treatment group, visit and treatment by visit interaction and a continuous covariate for baseline NT -proBNP (log -transformed). An unstructured covariance matrix 
will be used to account for the correlation between measurements of the same subject. Changes from baseline to all regular visits in 6MWD will be analyzed using the same model, but with a covariate for baseline 6MWD. Absence of worsening from baseline to all regular visits in WHO FC will be summarized 
by treatment group using descriptive statistics. Subjects in WHO FC IV at baseline will be excluded from this analysis. Unsatisfactory clinical response will be summarized by treatment group using descriptive statistics. This analysis will also be performed excluding subjects who already have an unsatisf actory ‘response’ at baseline (i.e., WHO FC  III or IV or a baseline 6MWD ≤  440 m, 
accompanied by NT -proBNP  ≥ 3 × ULN ). 
The number of treatment  goals met at Week 26 (0 –5) will be compared between treatment 
groups using the Cochran- Mantel -Haenszel test, stratified  by baseline WHO FC and 
6MWD (≤  440 m versus > 440 m). This analysis will also be performed excluding subjects 
who already had one or more goals met at baseline.  
Analysis of efficacy variables between EOMOP and EOT (i.e., after the main observation 
period) will be described in the SAP.  11.3.5 Analysis of the safety variables 
All safety analyses will be performed on the Safety S et using descripti ve statistics. Where 
indicated, safety analyses will also be performed on the subset of subjects who received at 
[STUDY_ID_REMOVED]
least one dose of double -blind study treatment  (i.e., selexipag or placebo). All safety data 
will be listed, with flags for quantitative abnormalities.  AEs in subjects  who were screened 
but not randomized will be listed. Safety analysis periods are described in Section 6.2.  11.3.5.1 Adverse events  
A treatment -emergent AE is any AE temporally associated with the use of any of the 
3 study treatment s. The number and percentage of subjects experiencing treatment 
emergent A Es and SAEs at least once will be tabulated by treatment group and by: 
• MedDRA s ystem organ class (SOC) and individual preferred term within each SOC, 
in descending order of incidence. 
• Frequency of subjects with events coded with the same preferred term, in  descending 
order of incidence.  
Furthermore, treatment -emergent AEs and SAEs will be tabulated as described above by 
severity and relationship to study treatment  (relationship separately by study treatment) .  
AEs leading to premature discontinuation of an y of the  3 study treatment s and AEs with 
outcome death will be summarized as described above.  
Listings will be provided for all reported AEs, including SAEs. In addition, separate listings will be provided for SAEs, for AEs leading to premature discontinuation of study treatment , and for AEs with outcome death.  
Additionally, AE and SAE tables will be provided for the subset of subjects who received at least one dose of double -blind study treatment . In these tables only AEs with onset 
between the first and l ast day of double -blind study treatment  will be included. AEs 
specifically related to double- blind study treatment will be tabulated as described above. 
AEs leading to premature discontinuation of double -blind study treatment and AEs on 
double- blind study treatment  with outcome  death will be summarized similarly. AEs and 
SAEs with onset between randomization and first day of double -blind study treatment will 
also be summarized.  For AEs occurring more than 30 days after discontinuation of one or more of the  study 
treatments, a dedicated analysis will be described in the SAP.  
11.3.5.2 Laboratory variables 
Descriptive summary statistics by visit and treatment group will be provided for observed values and absolute changes from baseline, in both hematology and blood che mistry 
laboratory tests. In order to minimize missing data and to allow for unscheduled visits, all recorded assessments up to EOT plus 30 days will be assigned to the most appropriate visit timepoint according to the best fitting time  window for that asse ssment.  
[STUDY_ID_REMOVED]
Actelion internal guidelines will be used for the definitions of marked abnormalities and for the standardization of numeric values obtained from different laboratories and/or using different normal ranges. Standard numeric laboratory variables are transformed to standard 
units. All laboratory data transferred are taken into account regardless of whether they correspond to scheduled (per protocol) or unscheduled assessments.  Marked laboratory abnormalities will be summarized for each laboratory variable by 
treatment group providing their incidence and frequency. Absolute values and changes from baseline of laboratory values during the course of the study will be summarized using the usual location and scale summary statistics by treatment group.  
For laboratory variables measured see Section  7.3.7.2.  
The number and percentage of subjects with treatment -emergent laboratory abnormalities 
will be tabulated by treatment group. 11.3.5.3 Vital signs and body weight  
Vital signs , HR, and body weight will be summarized at each study visit using the usual 
location and scale summary statistics by treatment group for both absolute values and changes from baseline. Subjects for whom no post -baseline value is available are excluded 
from the analysis of the changes from baseline in the Safety Set.  
11.3.6 Analysis of other variable(s)  
The individual maintenance dose for selexipag (or placebo) —defined as the dose to which a subject was exposed for the longest duration during the maintenance period— will be 
summarized using descriptive statistics.  
11.4 Interim analyses 
A formal interim analysis is planned  at information time of 0.33, i.e., when 33% of planned 
enrolled subjects in each arm have  completed  their Week 26 visit assessment or 
prematurely discontinued the study.  This interim analysis is intended to test for futility  (non-binding), in order  to prevent 
continuing treating subjects with triple combination therapy if  it is unlikely to show a 
clinical benefit for the subjects .  
However, as the interim analysis is designed to  assess the efficacy of the triple v ersus the 
dual combination, it is not considering all safety aspect s. Thus, an IDMC will review the 
efficacy, safety and  tolerability data at regular intervals  prior to and after the interim 
analysis .  
[STUDY_ID_REMOVED]
Access to randomization information will be limited to the independent SAC which will 
prepare all unblinded outputs for the interim analysis and for the  regular  IDMC  reviews . 
The SAC will be represented by an independent statistician.   
The interim analysis will be formally perfo rmed on the primary efficacy  endpoint. 
However , to ensure adequate and sufficient data for the interpretation and decision making , 
descriptive statistics will also be provided for other efficacy endpoints, selected safety variables (adverse events, selected lab oratory  abnormalities), exposure , and demographic 
data.   
11.5 Sample size  
11.5.1 Sample size justification  
Table 3 shows published PVR data from studies of initial  dual therapy (bosentan and 
epoprostenol [ Humbert 2004, Kemp 2012, Sitbon 2017] ) and initial  triple therapy 
(bosentan, epoprostenol and sildenafil  [Sitbon 2014] ). In addition, unpublished data from 
initial dual therapy were included  [Sitbon 2015, unpublished]. 
The four studies of initial dual therapy reported reductions (calculated) of PVR from 
baseline ranging from 40% to 54% [Sitbon 2017 ]. The observational study of initial triple 
therapy reported a reduction  (calculated)  of PVR of 68% (95% CI:  62%–74%) 
[Sitbon 2014].  
For the anticipated treatment difference (tr iple versus dual therapy group) it should be 
noted that the data from Table 3 are from different  studies that may not be fully comparable 
and that the information on initial triple therapy is limited (n  = 18). Taking into account 
those limitations (as well as the possibly less pronounced PVR reduction in subjects that do not complete 26 weeks of treatment) it is anticipated that the reduction in PVR from baseline in the dual therapy group is approximately 50% (GMR  = 0.50), whereas the PVR 
reduction in the triple therapy  is approximately 60 % (GMR  = 0.40) , corresponding to a  
ratio of geometric means of 0.80 (2 0% difference in favor of triple therapy) . This 
corresponds to a treatment difference on log  scale of −0.223 (i.e., log(0.40)  
–log(0.50)).  
An integrated analysis of two bosentan studies (BENEFIT, AC -052- 366, and EARLY, AC -
052-364) and one macitentan study (the hemodynamic sub- study of SERAPHIN, AC -055-
302) suggested that the within group standard deviation (SD) of the log -transformed ratio 
of Week 26 to baseline PVR is 0.41 (90% CI:  0.39–0.43). This is in line with the published 
PVR data where SD ranged from 0.38 to 0.44. For this trial, a more conservative SD  = 0.5 
on the log- scale was assumed.  
[STUDY_ID_REMOVED]
Considering a one-step analysis, i.e., no interim analysis, t o detect a t reatment difference 
of −0.223 with an SD of 0.5 (both on log -scale), a total of 212 subjects ( 106 per group) 
would be needed for 90% power (two- sided α  = 0.05). 
However , this trial is considering an early stopping for futility , which impacts the overall 
number of subjects . Under the same hypothesis, and considering a group sequential design, 
with a Poco ck boundary, and a non-binding interim analysis performed at information time  
0.33, the number of subjects needed to demonstrate this difference  (i.e., –0.223) at the final 
analysis  is increased to 238 subjects .  
The interim analysis is to be performed when 33% of the planned total number of subjects  
have completed the Week 26 PVR assessment or prematurely discontinued the study. 
Under those assumptions and considering the current selected boundary , it is expected that 
the study should be stopped if a reduction compared to placebo (on log scale)  lower than 
or equal to 0.042 is observed (assuming  equa l SD of 0.5) . In other words , H1 (reduction of 
approximately  0.223 on a log scale compared to placebo) is to be rejected if a 
p-value ≥  0.706 is observed at interim analysis  [Table 4] .  
Table 3 Mean and SD for PVR, log- transformed PVR and change from 
baseline on log- scale  
  N Mean  
dyn.s-1cm-5 SD 
dyn.s-1cm-5 SD 
(log-
scale)  Mean  
(log-
scale)  GMR  
(% red)2 
[95% CI]  
Dual Therapy         
Humbert 2004  Baseline 22 1511  605.1  0.39 7.25  
 Week 16  22 947 487.8  0.49 6.74  
 CFB1 22 - - 0.44 −0.51 0.60 (40%)  
[27% –50%]  
Kemp 2012  Baseline 23 1493  398 0.26 7.27  
 Month 4  23 784 364 0.44 6.57  
 CFB 23 - - 0.38 −0.71 0.49 (51%)  
[42% –58%]  
Sitbon 2015 (unpublished)  Baseline 52 1076  385 0.35 6.92  
 Month 4  52 620 292 0.45 6.33  
 CFB 52 - - 0.41 −0.59 0.55 (45%)  
[38% –51%]  
Sitbon 2017  Baseline 16 808 312 NC3 NC3  
 Week 16  16 384 184 NC3 NC3  
 CFB 16 - - NC3 NC3 0.46 (54%)  
[STUDY_ID_REMOVED]
  N Mean  
dyn.s-1cm-5 SD 
dyn.s-1cm-5 SD 
(log-
scale)  Mean  
(log-
scale)  GMR  
(% red)2 
[95% CI]  
[48% –60%]  
Triple Therapy         
Sitbon  2014  Baseline 18 1718  627 0.35 7.39  
 Month 4  18 564 260 0.44 6.24  
 CFB 18 - - 0.40 −1.15 0.32 (68%)  
[62% –74%]  
The means and SDs for untransformed PVR were taken from the publications, whereas the means and SDs for 
log-transformed PVR were calculated from those.  
1 Change from baseline. For the SD on log  scale a correlation of 0.5 was assumed between baseline and post -baseline.  
2 Geometric Mean Ratio to baseline (percentage reduction from baseline) . 
CFB = change from baseline; CI = confidence interval; GMR = g eometric mean ratio; PVR  = pulmonary vascular 
resistance; SD = standard deviation.  
3 NC = “ Not Calculated ” as treatment effect is directly provided in reference.  
 
11.5.2 Sample size sensitivi ty 
Table 4 shows the sample sizes when the assumptions about PVR reduction from baseline (50% in the dual therapy group versus 60% in the triple therapy group) are not entirely met. For the dual therapy group 40% to 60% reduction was considered and for the triple therapy group an additional 10% to 15% reduction was assumed. 
Table 4 Sample sizes needed for 90% power at final analysis, and stopping  
value for futility at interim analysis (two -sided α  = 0.05, SD = 0.5, 
information time = 0.33) 
PVR 
reduction 
in dual 
therapy 
group  PVR 
reduction 
in triple 
therapy 
group  Treatment 
effect  
GMR  
(% red)(2) Number 
of 
subjects  Number of 
subjects at 
interim 
analysis  Stop for futility if 
PVR reduction in 
triple therapy 
group ≤ (1) Stop for futility if 
p-value ≥  
40% 55% 0.75 (25%)  144 48 43.21 % 0.704  
40% 50% 0.83 (17%)  357 119 42.06 % 0.703  
50% 65% 0.70 (30%)  91 31 53.19 % 0.713  
50% 60% 0.80 (20%)  238 79 52.06 % 0.706  
60% 75% 0.63 (37%)  54 18 63.34 % 0.705  
60% 70% 0.75 (25%)  144 48 62.21 % 0.704  
Retained scenario (dual: 50% / triple: 60%)  appears in bold. PVR = p ulmonary vascular resistance, SD  = standard 
deviation.  
(1) Lowest PVR reduction in the triple combination below which, for the corresponding dual therapy PVR reduction, the 
difference with the dual therapy implies rejection of H1.  
(2) Geometric Mean Ratio  (GMR) of triple therapy over dual therapy  (percentage reduction).  
 
[STUDY_ID_REMOVED]
It can be seen that the proposed sample size of 238 subjects is robust to most deviations 
from the assumptions. Calculations were done using software EAST version 6.4. 
12 DATA HANDLING 
12.1 Data collection 
The investigator/delegate is responsible for ensuring  the accuracy, completeness, and 
timeliness of the data reported. All source documents should be completed in a neat, legible manner to ensure accurate interpretation of the data. Data reported in the  eCRF derived 
from source documents must be consistent with the source documents. Case Report Form ( CRF ) data will be captured via electronic data capture (using the Rave 
system provided by Medidata Solutions, Inc., a web- based tool). The investigator and sit e 
staff will be trained to enter and edit the data via a secure network, with secure access features (username, password , and identification – an electronic password system). A 
complete electronic audit trail will be maintained. The investigator/delega te will approve 
the data (i.e., confirm the accuracy of the data recorded) using an electronic signature (according  to 21 CFR  Part 11).  
Subject Screening data will be completed for all subjects (i.e., eligible and non -eligible) 
through the IRT system and  eCRF . 
For each subject enrolled, regardless of study treatment initiation, an  eCRF  must be 
completed and signed by the investigator/delegate. This also applies to those subjects who fail to complete the study. If a subject withdraws from the study, the reason is noted in the 
eCRF . However, the subject is not obliged to provide a reason. 
12.2 Maintenance of data confidentiality 
The investigator/delegate must ensure that data confidentiality is maintained. On  eCRF s or 
other documents (e.g., documents attached to SAE reports) submitted to Actelion  and any 
external service providers , subjects must be identified only by number, and never by name 
or initials , hospital numbers , or any other identifier . The investigator/delegate must keep a 
subject identification code list, at the site, showing the screening/ randomization number, 
the subject ’s name, date of birth, and address or any other locally accepted identifiers. 
Documents identifying the subjects (e.g., signed ICFs) must not be sent to Actelion, and 
must be kept in strict confidence by the investigator/delegate.  
12.3 Database management and quality control 
Electronic CRFs will be used for all subjects. The investigator /delegate will have access to 
the site  eCRF  data until the database is closed . Thereafter, they will have read -only access.  
The eCRF  must be kept current to reflect subject status at any timepoint during the course 
of the study.  
[STUDY_ID_REMOVED]
While entering the data, the investigator/delegate will be instantly alerted to data queries by valid ated programmed checks. Additional data review will be performed by Actelion 
on an ongoing basis to look for unexpected patterns in data and study monitoring. If discrepant data are detected, a query specifying the problem and requesting clarification will be issued and visible to the investigator/delegate via the  eCRF . All electronic queries 
visible in the system either require a data correction (when applicable) and a response from the investigator/delegate to clarify the queried data directly in the  eCRF , or simply a data 
correction in the  eCRF . The investigator/delegate must, on request, supply Actelion with 
any required background data from the study documentation or clinical records. This is particularly important when errors in data transcription are suspected. In the case of regulatory a uthority queries, it is also necessary to have access to the complete study 
records, provided that subject confidentiality is protected. This process will continue until database closure. Laboratory samples will be pro cessed through a central laboratory and the results will be 
loaded  electronically in to the clinical database [ for exceptions see Section  7.3.7.1] . 
After the database has been declared complete and accurate, the database will be closed. Any changes to the database after that time may only be made as described in the appropriate SOP. Af ter database closure, the investigator will receive the  eCRF s of the 
subjects pertaining to her/his site (including all data changes made) on electronic media. 
13 PROCEDURES AND GOOD CLINICAL PRACTICE 
13.1 Ethics and Good Clinical Practice 
Actelion and the investi gators will ensure that the study is conducted in full compliance 
with the latest version s of ICH-GCP Guidelines, the principles of the “ Declaration of 
Helsinki”, and with the laws and regulations of the country in which the research is 
conducted. 
13.2 Independ ent Ethics Committee / Institutional Review Board 
The investigator will submit this protocol and any related document provided to the subject (such as Subject Information Leaflet used to obtain informed consent) to an IRB or IEC. Approval from the committe e must be obtained before starting the study, and must be 
documented in a dated letter to the investigator, clearly identifying the study, the documents reviewed, and the date of approval. Modifications made to the protocol  or subject information leaflet  after receipt of the 
approval must also be submitted as amendments by the investigator to the IRB/IEC in accordance with lo cal procedures and regulations [ see Section  13.6]. 
[STUDY_ID_REMOVED]
A list of members participating in the IRB/IEC meetings must be provided, including the names, qualifications, and functions of these members. If that is not possible, the attempts made to obtain this information along with an explanation as to why it cannot be obtained or disclosed must be documented in the study documentation. If a study staff member was present  during a meeting, it must be clear that this person did not vote. 
13.3 Informed consent  
It is the responsibility of the investigator/delegate to obtain informed consent according to ICH-GCP guidelines and local regulations from each individual participating in  this study 
and/or legal representative. The investigator/delegate must explain to subjects that they are completely free to refuse to enter the study, or to withdraw from it at any time for any reason  and without having to provide any justification. 
The I CF will be provided in each  country’s local language(s).  
Site staff authorized to participate to the consent process and/or to obtain consent from the subject and/or legal representative will be listed on Actelion Delegation of Authority form. A study phys ician must always be involved in the consent process. 
The subject and/or legal representative must sign, personally date and time (if appropriate) the ICF before any study -related procedures (i.e., any procedures required by the protocol) 
begin. The ICF must also be signed, personally dated and timed (if the first study -mandated 
procedure was performed on the same day informed consent was obtained) by the authorized site staff listed on Actelion Delegation of Authority form. A copy of the signed and dated I CF is given to the subject and/or legal representative; the 
original is filed in the site documentation.The informed consent process must be fully documented in the subject ’s medical records . This must include the study reference, the 
subject number, the date and, if applicable, time when the subject was first introduced to 
Actelion clinical study, the date  and, if applicable,  time of consent, who participated in the 
consent discussion, who consented the subject , and any additional person present during 
the consent process (e.g., subject family member), a copy of the signed ICF given to the 
subject / legal representative.  
In the case that the site would like to recruit subjects who are considered as vulnerable 
(e.g., subject cannot read or write , does not speak or understand the ICF language), 
additional measures must be implemented in order to ensure subject ’s rights are respected 
and the consent obtained is legally valid. Actelion, the regulatory authorities (if applicable) , 
and the IRB/IEC must be informed prior to the recruitment. The consent process (e.g., involvement of an impartial witness) must be fully described, submitted to, and approved by the IRB/IEC, according to procedures and before subjects are recruited . 
[STUDY_ID_REMOVED]
13.4 Compe nsation to subjects and investigators 
Actelion provides insurance in order to indemnify (with both legal and financial coverage) the investigator/site against claims arising from the study, except for claims that arise from malpractice and/or negligence.  
The compensation of the subject in the event of study -related injuries will comply with 
applicable regulations. 
13.5 Protocol adherence/compliance 
The investigator must conduct the study in compliance with the approved version of the protocol and must not implement any deviation/change from the protocol, except when deviation is necessary  to eliminate an immediate hazard to the subject.  
If a protocol deviation occurs, the investigator/delegate will inform Actelion or its representative, in a timely manner. The in vestigator/delegate must document and explain 
any deviation from the approved protocol. Deviations considered to be a violation of GCP must be reported to the  IRB/IEC and regulatory authorities according to Actelion or 
(overruling) local requirements. 
13.6 Protocol amendments 
Any change to the protocol can only be made through a written protocol amendment. A protocol amendment must be submitted to IRB/IEC and regulatory authorities, according to their requirements.  
13.7 Essential documents and retention of documents 
The investigator/delegate must maintain adequate records necessary for the reconstruction and evaluation of the study. A number of attributes are considered of universal importance to source data and the records that hold those data. These include that the data and records are accurate, legible, contemporaneous, original (or certified copy), attributable, complete, consistent, enduring, and available when needed.  
These records are to be classified into two different categories of documents: ISF and 
subject clinical source documents.  
These records must be kept by the investigator for as long as is necessary to comply with Actelion ’s requirements ( i.e., as specified in the clinical study agreement), and national 
and/or international regulations, whichever would be the longest period. If the investigator cannot guarantee this archiving requirement at the site for any or all of the documents, special arrangements, respecting the data confidentiality, must be made between the investigator and Actelion to store the se documents outside the site, so that they can be 
retrieved in case of a regulatory inspection. No study document should be destroyed without prior written approval from Actelion. Should the investigator wish to assign the 
[STUDY_ID_REMOVED]
study records to another party, or move them to another location, Actelion must be notified in advance.  
If the site is using an electronic/computerized system to store subject medical records, it can be used for the purpose of the clinical study if it is validated (as per 21 CFR Part 11 or equivalent standard) and if the monitor has been provided personal and restricted access to 
study subjects only, to verify consistency between electronic source data and the eCRF  
during monitoring visits.  
If the site is using an electronic/computerized system to store subject medical records but it could not be confirmed that the system is validated or if the monitor could not be provided access to the system, the site is requested to print the complete set of source data needed for verification by the m onitor. The print -outs must be numbered, stapled together with a 
coversheet, signed and dated by the investigator/delegate to confirm that these certified copies are exact copies having the same information as the original subject ’s data. The 
printouts wil l be considered as the official clinical study records  and must be filed either 
with the subject medical records or with the subject’s eCRF . 
In order to verify that the process the site uses to prepare certified copies is reliable, the monitor must be able  to observe this process and confirm that the comparison of the source 
documents and the certified copy did not reveal inconsistencies. The monitor does not need to verify this process for all data of all subjects but at least for some of them (e.g., first subject; regular check during the study of critical data like inclusion/exclusion criteria, endpoints for some subjects) as per Actelion’ s instructions. If it were not possible for the 
monitor to observe this process, it would not be possible to rely on t he site ’s certified copies 
and therefore the site cannot be selected for the clinical study. 
13.8 Monitoring 
Prior to study start, a site initiation visit (SIV) will be performed after the required essential study documents are approved by Actelion. The study treatment will be shipped to the site upon approval of the required essential documents. The PI must ensure that all site personnel involved in the study are  present during the SIV  
and will dedicate enough time to it. Site Information Technology support should also be available during the initiation visit.  
The SIV must be completed before the site can start the screening of study subjects. Following the SIV, a copy of the completed initiation visit report and follow- up letter will 
be provided to the PI and filed in the  ISF. 
During the study, the monitor will contact and visit the site regularly and must be permitted , 
on request, to have access to study facilities and all source documents needed to verify 
adherence to the protocol and the completeness, consis tency , and accuracy of the data being 
[STUDY_ID_REMOVED]
entered in the  eCRF s and other protocol -related documents. Actelion monitoring standards 
require full verification that informed consent has been provided, verification of adherence to the inclusion/exclusion criteria,  documentation of SAEs, and the recording of the main 
efficacy, safety , and tolerability endpoints. Additional checks of the consistency of the 
source data with the  eCRF s will be performed according to the study -specific monitoring 
plan. The frequency of t he monitoring visits will be based on subject recruitment rate and 
critical data collection times.  
The PI must ensure that the  eCRF  is completed after a subject ’s visit ( site visit or phone 
call), and that all requested subject files (e.g., ICFs, medical n otes/charts, other 
documentation verifying the activities conducted for the study) are available for review by the monitor. The required site personnel must be available during monitoring visits and allow adequate time to meet with the monitor to discuss s tudy related issues.  
The investigator agrees to cooperate with the monitor(s) to ensure that any issues detected in the course of these monitoring visits are resolved. If the subject is hospitalized or dies in a hospital other than the study site, the investigator is responsible for contacting that hospital in order to document the SAE , in accordance with local regulations . 
A close- out visit will be performed for any initiated site when there are no more active 
subjects and all follow -up issues have been resolved. In case a site does not enroll any 
subjects, the close -out visit may be performed prior to study database closure at the 
discretion of Actelion. 
13.9 Investigator Site File 
Each site will be provided with an ISF prior to the initiation visit. It will contain all the essential documents that are required to always be up- to-date and filed at site as per ICH  
E6 GCP Section  8. 
The ISF will include a table of content listing the essential documents. All study -related 
documentation must be maintained in the ISF.  
In some cases, exceptions can be discussed with the monitor regarding the filing of the study documents outside the ISF. It should be clearly documented where each document is filed. This note to file should be present in the specific tab of the document in the ISF. The ISF must be stored in a secure and access -restricted  area during and after the study. It 
must be kept by the site for as long as needed to comply with any applicable rules and regulations, ICH -GCP , as well as instructions from Actelion. If the site needs to transfer 
the ISF to another location and/or if site facility can no longer store the ISF, the PI  must 
inform Actelion immediately.  
[STUDY_ID_REMOVED]
If the PI  will change, or if the site will relocate, the monitor  must be notified as soon as 
possible. 
13.10  Audit  
Actelion ’s Global Quality Management  representatives may audit the investigator site 
(during the study or after its completion). The purpose of this visit will be to determine the investigator ’s adherence to ICH -GCP, the protocol, and applicable regulations ; adherence 
to Actelion ’s requirements (e.g., SOPs)  will also be verified. Prior to initiating this audit, 
the investigator will be contacted by Actelion to arrange a time for the audit.  
The investigator and staff must cooperate with the auditor(s) and allow access to all study documentation (e.g., subject records) and facilities. 
13.11  Inspections 
Regulatory authorities and/or IRB/IEC may also conduct an inspection of Actelion’ s 
clinical study (during the study or after its completion).  
Should an inspection be announced by a regulatory a uthority and/or IRB/IEC, the 
investigator must inform Actelion immediately (usually via the monitor)  that such a request 
has been made.  
The investigator and staff must cooperate with inspector(s) and allow access to all study documentation (e.g., subject records) and study facilities. 
13.12  Reporting of study results and publication 
Study results will be documented in a clinical study report that will be signed by Actelion representatives and  the coordinating inve stigator (or PI for single -center studies).  
The coordinating investigator and the S C, if any, will have the opportunity to review the 
analysis of the data and to discuss the interpretation of the study results with Actelion prior to publication. Actelion will post results  from this clinical study on Actelion ’s Clinical Trial Register and 
on external/national registries, as required by local law .  
Actelion ’s Policy on Disclosure of Clinical Research Information can be found at: 
http://www.actelion.com/documents/corporate/policies -charters/policy -clinical -research -
information.pdf In accordance with the Good Publication Practices and ethical practice, the results of the study will be submitted for publication in a peer -reviewed jou rnal. Study results can be 
submitted for presentation at a congress before publication in a peer -reviewed journal. 
[STUDY_ID_REMOVED]
Authorship will be determined in accordance with the International Committee of Journal Editors (ICMJE) criteria , and be based on: 
• substantia l contributions to the conception or design of the study, or the acquisition, 
analysis , or interpretation of data; and 
• drafting of the publication or critical review for important intellectual content; and  
• providing final approval of the version to be published; and 
• agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. 
The list of authors of any publication of study results may include representatives of Actelion and will be determined by mutual agreement.  
Any study -related publication written independently by investigators must be submitted to 
Actelion for review at least 30 days prior to submission for publication or presentation. Upon review, Actelion may provide comments, and may also request alterations and/or deletions for the sole purpose of protecting its confidential information and/or patent rights. Neither the institution nor the investigator should permit publication during such a review period. Actelion ’s Policy on Scientific Publications can be found at: 
http://www.actelion.com/documents/corporate/policies -charters/policy -scientific -
publications.pdf 
14 REFERENCES 
[Adcirca SmPC] Adcirca Summary of Product Characteristics.  
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001021/WC500032789.pdf.  
[Adcirca USPI] A dcirca Prescribing Information.  
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022332s009lbl.pdf.  
[ATS Statement  2002] Guidelines for the Six -Minutes Walk Test. Am J Respir Crit Care 
Med. 2002;166:111-7.  
[Benza 2010] Benza RL, Miller DP, Gomberg- Maitland M, Frantz RP, Foreman AJ, 
Coffey CS. Predicting survival in pulmonary arterial hypertension insights from the registry to evaluate early and long -term pulmonary arterial hypertension disease 
management (REVEAL). Circulation . 2010;122:164-172.  
[Chadha  2009] Chadha C, Pritzker M, Mariash CN. Effect of epoprostenol on the thyroid 
gland: enlargement and secretion of th yroid hormone. Endocr Pract . 2009;15: 
116-21.  
[STUDY_ID_REMOVED]
[ESC Guidelines] ESC Guidelines on the management of cardiovascular diseases during 
pregnancy. Eur Heart J. 2011;32:3147-3191. 
[Galiè  2013] Galiè N, Corris PA, Frost A, Girgis RE, Granton J, Jing ZC. Updated 
Treatment Algorithm of Pulmonary Arterial Hypertension. J Am Coll Cardiol. 
2013;62:D60-72.  
[Gali è 2015a ] Gali è N, Albert Barbera J, Frost A, Ardeschir Ghofrani H, Hoeper M, 
Mclaughlin V, et al. AMBITION: Initial use of ambrisentan plus tadalafil in 
pulmona ry arterial hypertension.  N Engl J Med. 2015;373:834-44.  
[Galiè  2015b] Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 
ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2015 doi:10.1093/eurheartj/ehv317.  
[Gomez -Arroyo 2015] Gomez -Arroyo J, Sakagami M, Syed AA, Farkas L, Van Tassell B, 
Kraskauskas D, et al . Iloprost reverses est ablished fibrosis in experimental right 
ventricular failure. Eur Respir J. 2015;45(2):449-62.  
[Hoeper 2013] Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M. 
Definitions and Diagnosis of Pulmonary Hypertension. J Am Coll Cardiol . 
2013;62: D42-50.  
[Humbert 2004] Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial 
hypertension. New Engl J Med. 2004;351:142-136.  
[Kemp 2012] Kemp K, Savale L, O ’Callaghan DS, Jaïs X, Montani D, Humbert M, et al . 
Usefulness of first -line combination therapy with epoprostenol and bosentan in 
pulmonary arterial hypertension: An observational study. J Heart Lung Transplant . 
2012;31:150-158.  
[Kylhammar 2014] Kylhammar D, Persson L, Hesselstrand R, Rådegran G. Prognosis and 
response to first -line single - and combination therapy in pulmonary arterial 
hypertension. Scand Cardiovasc J. 2014;10:1-23.  
[Macitentan IB] Investigator’ s Brochure. Macitentan ACT -064992. Endothelin receptor 
antagonist, Version 12. Actelion Pharmaceuticals Ltd, November 2014.  
[Marvisi  2013] Marvisi M, Balzarini L, Mancini C, Mouzakiti P. Thyroid gland and 
pulmonary hypertension. What’ s the link? Panminerva Med . 2013;55:93-7.  
[McLaughlin  2013] McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, 
Mehta S, et al. Treatment g oals of pulmonary hypertension. J Am Coll Cardiol. 
2013;62:D73-81.  
[STUDY_ID_REMOVED]
[Nickel 2012] Nickel N, Golpon H, Greer M, et al. The prognostic impact of follow -up 
assessments in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2012;39:589-596.  
[Oudiz 2013] Oudiz RJ. Death in Pulmonary Arterial Hypertension. Am J Respir Crit Care 
Med. 2013;188(3):269-70.  
[Pulido 2013] Pulido T, Adzerikho I, Channick RN, Delcroix M, Galiè N, Ghofrani A. 
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med . 2013;369:809-18.  
[Selexipag IB] Investigator’s Brochure. Selexipag ACT -293987, IP receptor agonist. 
Actelion Pharmaceuticals Ltd, Version 13, September  2018. 
[Simonneau 2013] Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, 
Ghofrani A. Updated Clinical Classification of Pulmonary Hypertension. J Am Coll Cardiol. 2013;62:D34-41.  
[Sitbon 2014] Sitbon O, Jais X, Savale L, Cottin V, Bergot E, Macari EA, et al . Upfron t 
triple combination therapy in pulmonary arterial hypertension: a pilot study. Eur Respir J . 2014; in press DOI: 10.1183/09031936.00116313.  
[Sitbon 2015] Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, et al. Selexipag 
for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522-33. 
[Sitbon 2017] Sitbon O, Canuet M, Picard F, Prevot G, Bergot E, Cottin V, et al. Initial 
Combination Therapy with Macitentan and Tadalafil in Newly Diagnosed Patients with Pulmonary Arterial Hypertension: Results from the OPTIMA Trial. Am J  Resp 
Crit Care Med 2017;195:A2297. 
 
[STUDY_ID_REMOVED]